Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

Search
Advanced Search
OPEN ACCESS
mobile search button mobile menu button

Articles

Page Path
HOME > Cancer Res Treat > Volume 54(2); 2022 > Article
Special Article Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2019
Mee Joo Kang1,2orcid, Young-Joo Won1,2,3orcid, Jae Jun Lee1,2, Kyu-Won Jung1,2, Hye-Jin Kim1,2, Hyun-Joo Kong1,2, Jeong-Soo Im4, Hong Gwan Seo1,3, The Community of Population-Based Regional Cancer Registries
Cancer Research and Treatment : Official Journal of Korean Cancer Association 2022;54(2):330-344.
DOI: https://doi.org/10.4143/crt.2022.128
Published online: March 16, 2022

1Korea Central Cancer Registry, National Cancer Center, Goyang, Korea

2Division of Cancer Registration and Surveillance, National Cancer Control Institute, National Cancer Center, Goyang, Korea

3National Cancer Center Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea

4National Cancer Control Institute, National Cancer Center, Goyang, Korea

Correspondence: Young-Joo Won, Korea Central Cancer Registry, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea,
Tel: 82-31-920-2015, Fax: 82-31-920-2179, E-mail: astra67@ncc.re.kr
* Regional Cancer Registry Committee Chang-Hoon Kim (Busan Cancer Registry, Pusan National University Hospital), Cheol-In Yoo (Ulsan Cancer Registry, Ulsan University Hospital), Yong-Dae Kim (Chungbuk Cancer Registry, Chungbuk National University Hospital), Young-Taek Kim (Daejeon/Chungnam Cancer Registry, Chungnam National University and Hospital), Chul Min Park (Jeju Cancer Registry, Jeju National University and Hospital), Jung-Ho Youm (Chonbuk Cancer Registry, Jeonbuk National University Hospital), Kyuhyoung Lim (Kangwon Cancer Registry, Kangwon National University Hospital), Nam-Soo Hong (Daegu/Gyeongbuk Cancer Registry, Kyungpook National University Medical Center), Sun-Seog Kweon (Gwangju/Jeonnam Cancer Registry, Chonnam National University Hwasun Hospital), Woo-Chul Kim (Incheon Cancer Registry, Inha University Hospital), Ki-Soo Park (Gyeongnam Cancer Registry, Gyeongsang National University and Hospital).
• Received: March 6, 2022   • Accepted: March 15, 2022

Copyright © 2022 by the Korean Cancer Association

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 29,811 Views
  • 990 Download
  • 228 Web of Science
  • 240 Crossref
  • 233 Scopus
prev next
Full Article

Download PDF Download PDF

  • Purpose
    The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2019.
  • Materials and Methods
    Incidence, survival, and prevalence rates of cancer were calculated using the Korea National Cancer Incidence Database, from 1999 to 2019, with survival follow-up until December 31, 2020. Deaths from cancer were assessed using causes-of-death data obtained from Statistics Korea.
  • Results
    In 2019, newly diagnosed cancer cases and deaths from cancer were reported as 254,718 (age-standardized rate [ASR], 275.4 per 100,000) and 81,203 (ASR, 72.2 per 100,000), respectively. For the first time, lung cancer (n=29,960) became the most frequent cancer in Korea, excluding thyroid cancer. The overall cancer incidence rates increased by 3.3% annually from 1999 to 2012, and decreased by 5.3% annually from 2012 to 2015, thereafter, followed by nonsignificant changes. The incidence of thyroid cancer increased again from 2016 (annual percentage change, 6.2%). Cancer mortality rates have been decreasing since 2002, with more rapid decline in recent years (annual decrease of 2.7% from 2002 to 2013; 3.3% from 2013 to 2019). The 5-year relative survival between 2015 and 2019 was 70.7%, which contributed to prevalent cases reaching over 2 million in 2019.
  • Conclusion
    Cancer survival rates have improved over the past decades, but the number of newly diagnosed cancers is still increasing, with some cancers showing only marginal improvement in survival outcomes. As the number of cancer survivors increases, a comprehensive cancer control strategy should be implemented in line with the changing aspects of cancer statistics.
  • Key words: Neoplasms, Incidence, Mortality, Survival, Prevalence, Korea
It is estimated that there were approximately 19.3 million new cancer cases and 10 million deaths from cancer worldwide in 2020 [1]. During this century, cancer is expected to surpass cardiovascular disease as the leading cause of premature death in most countries [2]. Cancer is the leading cause of death in Korea [3]. In order to reduce the pain and social burden caused by cancer and to promote public health, the National Plan for Cancer Control has been implemented since 1996, and the 4th stage is in effect from 2021. As a fundamental part of the Plan, the Korea Central Cancer Registry (KCCR) publishes cancer registration statistics every year. The current study reports the most recent nationwide statistics on cancer incidence, survival, prevalence, and mortality, and their temporal trends.
1. Data sources
Annual cancer statistics in Korea are calculated using a national and population-based database of cancer occurrence, the Korea National Cancer Incidence Database (KNCI DB). Every year, the KCCR collects information on patients diagnosed with cancer at hospitals across the country during the past year. The data from previous year is backed up with information compiled by central and 11 regional cancer registries, including information on cancer patients missed in hospital-based registrations. Hence, it takes two years to complete and calculate the year’s KNCI DB and cancer statistics. The KCCR has reported nationwide statistics since 1999; other detailed information on the KCCR and KNCI DB is provided in our previous report [4]. Completeness is an important indicator of data quality, and the 2019 KNCI DB was estimated to be 98.3% complete using the method proposed by Ajiki et al. [5].
Annual mid-year population data and recently updated mortality data including causes of death from 1983 were obtained from Statistics Korea [3]. To confirm the validity of individual vital statuses used in survival and prevalence calculation, the KNCI DB was linked to both mortality and population resident registration data, which were obtained from the Ministry of the Interior and Safety.
2. Cancer classification
All cancer cases had been registered in accordance with the International Classification of Diseases for Oncology, 3rd edition (ICD-O-3) [6]. The range of cancers to be registered and used for the national statistics calculation was limited to records with a behavior code of “/2 (carcinoma in situ)” or “/3 (malignant),” from the morphology (i.e., histology) codes of ICD-O-3, by which a patient was initially enrolled in the KNCI DB. Similar to previous reports, malignant cancer cases and their statistics were mainly assessed in this article. In addition, the supplementary incidence statistics for carcinoma in situ cases were also calculated separately, using 2019 KNCI DB.
For the convenience of classification and reporting, the ICD-O-3 codes were converted to the classification of the International Classification of Diseases, 10th edition (ICD-10) [7]. Exceptionally, some hematopoietic diseases (myeloproliferative disorders/myelodysplastic syndromes) are not classified as malignant cancer in ICD-10 classification, therefore their ICD-O-3 codes were used without any conversion. For mortality data, causes of death were coded according to the ICD-10.
We adopted cancer classifications with 24 and 61 types; the former was a modified classification based on the GLOBOCAN cancer dictionary [8], and the latter was the taxonomy used in “Cancer Incidence in Five Continents” [9], and both of them were provided by the International Association of Cancer Registries. In this article, cancer classification with 24 types of cancer was used for description. The summary staging system developed under the Surveillance, Epidemiology, and End Results (SEER) program (i.e., SEER summary staging) [10] was used to categorize the extent of tumor invasion or metastasis.
3. Statistical analyses
Incidence, mortality, and prevalence rates were expressed as crude rates (CRs) or age-standardized rates (ASRs) per 100,000 people. The CR was defined as the total number of newly diagnosed (for incidence) or deceased (for mortality) cases in a year divided by the mid-year population. The ASR was defined as the weighted average of the age-specific rates in which the weights represent the proportions of people in the corresponding age groups in a standard population [11]. ASRs were standardized using Segi’s world standard population [12]. The cumulative risk of developing cancer from birth to life expectancy during 2019 in Korea were also assessed, assuming no other cause of death (i.e., by simply calculating the sum of the age-specific cancer rates from birth to life expectancy), as follows [11]:
Cumulative risk of developing cancer from birth to life expectancy=100×(1-e-cumulative rate100)
Trends in ASRs were estimated using Joinpoint regression [13], with a maximum number of two joinpoints. The results were summarized as annual percentage changes with the best model fit, based on a linear model for the natural log-transformed ASRs.
The survival rate of cancer patients, diagnosed between 1993 and 2019, was calculated based on the results of follow-up until December 31, 2020. The 5-year relative survival rate was defined as the ratio of observed survival of cancer patients to expected survival in the general population, adjusting the effects of other causes of death using the standard population life table provided by Statistics Korea [3]. Relative survival rates were estimated using the Ederer II method [14] with some minor corrections, based on an algorithm devised by Paul Dickman [15]. Trends in 5-year relative survival rates were evaluated as percent differences in survival rates between 1993–1995 and 2015–2019.
Prevalent cases were defined as the number of cancer patients alive on January 1, 2020 among all the patients diagnosed with cancer between 1999 and 2019. Limited-duration prevalence was calculated using SEER*Stat 8.3.8 software (National Cancer Institute, Bethesda, MD). p < 0.05 was considered statistically significant. SEER*Stat, Joinpoint 4.8.0 (National Cancer Institute), and SAS ver. 9.4 (SAS Institute, Cary, NC) were used for statistical analyses.
1. Incidence
In 2019, a total of 254,718 people were newly diagnosed with cancer in Korea, of which 52.7% (134,180 cases) were men and 47.3% (120,538 cases) were women (Table 1). The five most diagnosed cancers in Korea were thyroid, lung, stomach, colorectal, and breast cancers; in men, lung and stomach cancers were followed by colorectal, prostate, and liver cancers, whereas breast and thyroid cancers were followed by colorectal, stomach, and lung cancers in women. These top five cancers in each sex accounted for 63.8% and 65.7% of all cancer cases in men and women, respectively. Thyroid cancer was the most frequent cancer from 2010 to 2014: its ranking fell after the debate on overdiagnosis in 2014, but recently rose again and regained the first rank in 2019. Excluding thyroid cancer, it is the first time in 2019 that lung cancer has surpassed stomach cancer to rank first in the incidence rate in Korea. Table 2 provides the CRs and ASRs of cancer incidence in 2019. The CR and ASR of all cancer incidence were 496.2 per 100,000 (523.9 for men and 468.5 for women) and 275.4 per 100,000 (296.6 for men and 267.4 for women), respectively. The difference between CR and ASR implies that majority of cancer patients in Korea belong to the elderly, as opposed to the world’s standard population, which has a higher proportion of young people. The overall lifetime probability of being diagnosed with any cancer was 37.9%, under the condition that one survives to the age that matches the life expectancy of the Korean population. That probability was higher in men (39.9%) than in women (35.8%) (data not shown).
There were marked differences in age-specific incidence rates (Fig. 1). In the childhood population (0–14 years), leukemia, brain and central nervous system (CNS) cancer, and non-Hodgkin lymphoma were the top three cancers in both sexes, accounting for 31.3%, 14.7%, and 13.9% of all cancer cases diagnosed in this age group, respectively. Thyroid cancer was the most common cancer in both sexes among the adolescent and young adult populations (15–34 years), accounting for 52.1% of all cancers diagnosed. The most common cancers in that age group, excluding thyroid cancer, were leukemia and colorectal cancer in men, and breast and cervical cancer in women. In the 35–64-year age group, men were most commonly diagnosed with stomach, colorectal, liver, and lung cancers (collectively accounting for 52.5%), while breast and thyroid cancers were the most common in women (collectively accounting for 54.8%). For those aged 65 years and above, lung and prostate cancers were the most common in men, while colorectal and lung cancers were the most common in women. Most cancers have shown to increase in incidence with age; the exceptions were thyroid cancer in both sexes and breast cancer in women, which showed the highest incidence in those in their 30–40s and 40–50s age groups, respectively (Fig. 2).
2. Mortality
Since the causes-of-death statistics were published in 1983, cancer has been the number one cause of death in Korea. As of 2019, a total of 81,203 people (61.9% men and 38.1% women) died of cancer, accounting for 27.5% of all deaths in Korea (Tables 1 and 3). The overall CR for cancer deaths was 158.2 per 100,000, and the rate was approximately 1.6 times higher for men than for women (Table 4). Lung cancer was the leading cause of cancer death in both sexes (CR, 53.5 per 100,000 in men and 19.0 per 100,000 in women), followed by liver and colorectal cancers in men, and colorectal and pancreatic cancers in women. When stratified according to the age at the time of death, the most common causes of cancer mortality in both sexes were as follows: leukemia in their 10s and 20s, breast cancer in their 30s, liver cancer in their 40s and 50s, and lung cancer among those 60 years old or older (data not shown).
3. Trends in cancer incidence and mortality
Changes in cancer incidence rates from 1999 to 2019 and mortality rates from 1983 to 2019 are depicted in Fig. 3. Compared to 1999, cancer incidence rates increased about 29.8% and mortality rates decreased about 37.3%, in 2019 (Table 5). The overall cancer incidence rates increased by approximately 3.3% per year until 2012, followed by a decline until 2015 with an annual decrease of 5.3%, and thereafter showed nonsignificant changes. In contrast, cancer mortality rates demonstrated nonsignificant changes until 2002, and decreased thereafter with an annual decrease of 2.7% until 2013, and a further decrease of 3.3% per year until 2019. These trends were observed similarly in both men and women, although the slopes of change were much more pronounced in women for incidence, and in men for mortality rates (S1 and S2 Tables).
Since 1999, breast, pancreas, kidney, and hematologic (leukemia and lymphoma) cancers, and that of some male or female reproductive organs (ovary, corpus uteri, prostate, and testis) have been continuously increasing. In both sexes combined, breast (especially for women) and kidney cancers displayed initial rapid increases and then lessened increases after 2007 and 2009, respectively. Prostate cancer demonstrated distinguished increase until 2009, followed by nonsignificant trend until 2015, and regained increasing trend thereafter. The remaining cancers with increasing trend revealed steady increases throughout the entire period. On the other hand, the incidences of colorectal and bladder cancers demonstrated increasing trends that have recently reversed significantly, with decreases starting in 2011 and 2004, respectively. In contrast, stomach and liver cancers demonstrated initial moderate decreasing trends until 2011 and 2009, respectively, followed by more rapid decreases thereafter; and cervical cancer showed marked decrease until 2007, however it showed lessened decrease thereafter until now. Lastly, the incidence of thyroid cancer increased significantly between 1999 and 2011, decreased significantly between 2011 and 2016, and increased again from 2016 (Table 5). These trends were observed similarly in both men and women, except for breast cancer in men and bladder cancer in women that revealed partially different results of trends from those described above. In men, decreasing trend of stomach, lung, and liver cancer throughout the period and colorectal cancer since 2011 were significant while prostate and kidney cancer had an increasing trend. In women, stomach, colorectal, liver, and cervix cancer had decreasing trend while breast and lung cancer revealed an increasing trend. The characteristic trend of thyroid cancer which changed rapidly in a short period of time, was more pronounced in women than in men (Fig. 4, S1 and S2 Tables).
The ASRs for mortality in most cancers have shown decreasing trends in Korea. Stomach cancer revealed continuous decreasing trends throughout the entire observed period for mortality, with more pronounced decreasing slopes in more recent periods. Liver and lung cancer mortality rates began to decrease in 2002 and 2001, respectively, followed by further rapid decreases starting in 2014. On the other hand, the mortality rates of colorectal, cervical, and thyroid cancers initially increased significantly until 2003; since then, the mortality rate from cervical cancer and thyroid cancer has decreased, and colorectal cancer has shown insignificant changes for 10 years and started to decrease from 2012 (Table 5). These trends were observed similarly in both sexes. However, breast cancer in women displayed significantly increasing mortality trends throughout the entire observed period, with less increasing trend after 2005 (Fig. 5, S1 and S2 Tables).
4. Survival rates
Over the past two decades, when cancer survival statistics have been compiled, the relative survival rates of cancer patients have increased significantly and steadily. The 5-year relative survival rates for all patients diagnosed with cancer in the recent 5 years, from 2015 to 2019 were 70.7% in both sexes; 64.5% in men and 77.3% in women (Table 6). The temporal increasing trends in survival rates, from 42.9% in 1993–1995 to 70.7% in 2015–2019, were maintained even after excluding thyroid cancer (from 41.2% in 1993–1995 to 66.5% in 2015–2019), which has an excellent prognosis with a 5-year relative survival rate of 100%.
After thyroid cancer, survival rates were the highest for testis and prostate cancers in men (95.0% and 94.4%, respectively) and breast cancer in women (93.6%). On the contrary, the survival rates were the lowest for cancers of the pancreas (13.9%), and gallbladder plus other and unspecified parts of the biliary tract (28.5%) in both sexes. Stomach cancer (both sexes), prostate cancer (men), lung cancer, and leukemia (women) were associated with outstanding improvements in survival rates over the observed period. In contrast, advances have been slow for cancers of the brain and CNS, pancreas in both sexes.
In terms of stage distribution at diagnosis and recent survival rates according to the SEER summary stage in each cancer, Fig. 6 shows the top 10 most common cancers for each sex in 2019. In men, stomach, kidney, and bladder cancers revealed the highest proportions of patients who were diagnosed at the localized stage (64.8%, 72.5%, and 72.2%, respectively), accompanied by the 5-year survival rates of 97.5%, 97.5%, and 86.4%, respectively. In contrast, lung and pancreatic cancers demonstrated the highest proportions of patients diagnosed at the distant metastatic stage, which approximated to 50%, with corresponding 5-year survival rates of 7.6% and 2.2%, respectively. In women, 58.7%, 63.4%, and 72.4% of breast, stomach, and uterine corpus cancers, respectively, were diagnosed at the localized stage, with 5-year survival rates of 98.8%, 95.9%, and 96.6%, respectively. However, more than 40% of lung and pancreatic cancers were diagnosed at the distant metastatic stage, with 5-year survival rates of 5.7% and 2.3%, respectively.
5. Prevalence rates
The total prevalent cancer cases in 2019 (identified as survivor at the time of January 1, 2020) were 2,147,503, surpassing 2 million since 2018 (Table 1). It suggested that one in 25 people (4.2% of the entire Korean population; 3.7% of men and 4.7% of women) has a history of being diagnosed with cancer. Of these, 996,051 (46.4% of all prevalent cases) were aged ≥ 65 years, indicating that one in eight people in that age group (16.4% of, or one in six, men and 10.3% of, or one in ten, women) would have experienced cancer (data not shown).
Table 7 provides the CRs and ASRs of prevalence for all cancers combined and for specific cancers. In total, the cancer prevalence rate for 2019 in Korea was 4,183.1 per 100,000 people. Thyroid cancer had the highest prevalence (CR, 900.2 per 100,000; 330.2 per 100,000 for men and 1,467.6 per 100,000 for women), followed by stomach cancer (CR, 621.3 per 100,000) and colorectal cancer (CR, 544.9 per 100,000). Prostate cancer in men and breast cancer in women revealed the highest prevalence rates (CR, 425.1 and 1,003.5 per 100,000, respectively).
The number of prevalent cases for common cancers, according to the time since cancer diagnosis, are described in Fig. 7. In total, 1,268,265 (59.1% of all prevalent cases) had survived > 5 years after cancer diagnosis, majority of them being survivors of thyroid, stomach, colorectal, and breast cancers. Another 462,265 (21.5% of all prevalent cases) have been alive 2–5 years after their cancer diagnosis, in which period they need regular follow-up; and the rest were 416,973 (19.4% of all prevalent cases) for whom it had been < 2 years since their cancer diagnosis, in which period they still need active cancer treatment.
6. Carcinoma in situ incidence
A summary of carcinoma in situ cases in 2019 is provided as a Supplementary Material (S3–S6 Tables, S7–S9 Figs.).
Since 2015, the number of new cancer patients in Korea has been increasing, but the ASRs of incidence did not reveal a significant change. In 2019, lung cancer has surpassed stomach cancer to rank first in the incidence rate for the first time, excluding thyroid cancer. During the past decade, the incidence of stomach, colorectal, liver, and cervical cancer has been declining while that of prostate and breast cancer have been on the rise since 1999. Thyroid cancer, which has decreased since 2012, has shown an increasing trend since 2015. The 5-year relative survival rate of cancer patients diagnosed in the past 5 years was 70.7%, which is steadily improving. Since 2018, the number of cancer survivors has exceeded 2 million, of which 59.1% are those who survived over 5 years. Cancer survival rates are increasing, but the number of newly diagnosed cancers and the prevalence of cancer continue to rise. National cancer control strategies should adapt to the changing aspects of cancer statistics.
crt-2022-128_S1_Table.pdf
crt-2022-128_S2_Table.pdf
crt-2022-128_S3_Table.pdf
crt-2022-128_S4_Table.pdf
crt-2022-128_S5_Table.pdf
crt-2022-128_S6_Table.pdf
crt-2022-128_S7_Fig.pdf
crt-2022-128_S8_Fig.pdf
crt-2022-128_S9_Fig.pdf
Acknowledgements
Special thanks to the tumor registrars (health information managers) of the Korea Central Cancer Registry (KCCR)-affiliated and non-KCCR-affiliated hospitals for data collection, abstracting, and coding. Additionally, we acknowledge the cooperation of the National Health Insurance Service and Statistics Korea for data support. This work was supported by the Health Promotion Fund of the Ministry of Health & Welfare (No. 2160830) and a research grant (No. 2211110) from the National Cancer Center, Republic of Korea.

Author Contributions

Conceived and designed the analysis: Won YJ.

Collected the data: Won YJ, Regional Cancer Registry Committee.

Contributed data or analysis tools: Kang MJ, Won YJ, Lee JJ, Jung KW, Kim HJ, Kong HJ.

Performed the analysis: Lee JJ.

Wrote the paper: Kang MJ, Won YJ.

Interpretation and review: Jung KW, Kong HJ.

Review and comment: Im JS, Seo HG.

Conflicts of Interest

Conflict of interest relevant to this article was not reported.

Fig. 1
The five common sites of cancer incidence by age group and sex for 2019 in Korea. (A) Men. (B) Women. Numbers in parentheses are age-specific incidence rates per 100,000. CNS, central nervous system.
crt-2022-128f1.jpg
Fig. 2
Age-specific incidence rates of common cancers for 2019 in Korea. (A) Men. (B) Women.
crt-2022-128f2.jpg
Fig. 3
Annual age-standardized cancer incidence and mortality rates by sex for all sites from 1983 to 2019 in Korea. Age standardization was based on Segi’s world standard population.
crt-2022-128f3.jpg
Fig. 4
Trends in age-standardized incidences of selected cancers by sex from 1999 to 2019 in Korea. (A) Men. (B) Women. Age standardization was based on Segi’s world standard population.
crt-2022-128f4.jpg
Fig. 5
Trends in age-standardized mortalities of selected cancers by sex from 1983 to 2019 in Korea. (A) Men. (B) Women. Age standardization was based on Segi’s world standard population. a)Cancers of cervix uteri, corpus uteri, and unspecified combined (C53–C55), due to their unclear classifications in the past.
crt-2022-128f5.jpg
Fig. 6
Five-year relative survival rates by stage at diagnosis and stage distribution of selected cancers by sex in Korea, 2015–2019. (A) Men. (B) Women. Staging according to the Surveillance, Epidemiology, and End Results stage categories. For each cancer type, stage categories do not total 100% because sufficient information was not available to stage all cases. a)Includes the gallbladder and other/unspecified parts of the biliary tract.
crt-2022-128f6.jpg
Fig. 7
Prevalent cases of common cancers by time since cancer diagnosis. Prevalent cases were defined as the number of cancer patients alive on January 1, 2020 among all cancer patients diagnosed between 1999 and 2019.
crt-2022-128f7.jpg
Table 1
Cancer incidence, deaths and prevalence by sex in Korea, 2019
Site/Type New cases Deaths Prevalent casesa)
Both sexes Men Women Both sexes Men Women Both sexes Men Women
All sites 254,718 134,180 120,538 81,203 50,281 30,922 2,147,503 943,518 1,203,985
Lip, oral cavity, and pharynx 3,969 2,863 1,106 1,298 997 301 29,516 19,723 9,793
Esophagus 2,870 2,573 297 1,554 1,425 129 12,086 10,769 1,317
Stomach 29,493 19,761 9,732 7,624 4,956 2,668 318,948 210,689 108,259
Colon and rectum 29,030 17,119 11,911 8,880 5,016 3,864 279,717 165,962 113,755
Liver 15,605 11,541 4,064 10,586 7,784 2,802 75,261 56,420 18,841
Gallbladderb) 7,383 3,896 3,487 4,988 2,568 2,420 25,505 13,185 12,320
Pancreas 8,099 4,150 3,949 6,396 3,424 2,972 14,964 7,562 7,402
Larynx 1,222 1,154 68 318 289 29 11,902 11,205 697
Lung 29,960 20,331 9,629 18,574 13,698 4,876 103,108 62,105 41,003
Breast 24,933 113 24,820 2,643 21 2,622 259,116 944 258,172
Cervix uteri 3,273 - 3,273 898 - 898 58,983 - 58,983
Corpus uteri 3,287 - 3,287 358 - 358 30,946 - 30,946
Ovary 2,888 - 2,888 1,234 - 1,234 24,259 - 24,259
Prostate 16,803 16,803 - 2,047 2,047 - 108,870 108,870 -
Testis 325 325 - 19 19 - 4,046 4,046 -
Kidney 6,026 4,155 1,871 983 666 317 50,674 34,270 16,404
Bladder 4,895 3,984 911 1,550 1,167 383 39,963 32,592 7,371
Brain and CNS 1,981 1,070 911 1,416 756 660 12,934 6,650 6,284
Thyroid 30,676 7,516 23,160 373 109 264 462,151 84,565 377,586
Hodgkin lymphoma 308 181 127 57 33 24 3,436 2,115 1,321
Non-Hodgkin lymphoma 5,388 3,117 2,271 1,856 1,081 775 37,971 21,544 16,427
Multiple myeloma 1,831 997 834 961 527 434 7,741 4,064 3,677
Leukemia 3,738 2,108 1,630 1,911 1,143 768 25,538 14,178 11,360
Other and ill-defined 20,735 10,423 10,312 4,679 2,555 2,124 149,868 72,060 77,808

CNS, central nervous system.

a) Limited-duration prevalent cases on January 1, 2019. These are patients who were diagnosed between January 1, 1999 and December 31, 2019 and who were alive on January 1, 2020. Multiple primary cancer cases were counted multiple times,

b) Includes the gallbladder and other/unspecified parts of the biliary tract.

Table 2
Crude and age-standardized cancer incidence rates by sex in Korea, 2019
Site/Type Crude incidence rate per 100,000 Age-standardized incidence rate per 100,000a)
Both sexes Men Women Both sexes Men Women
All sites 496.2 523.9 468.5 275.4 296.6 267.4
Lip, oral cavity, and pharynx 7.7 11.2 4.3 4.3 6.5 2.4
Esophagus 5.6 10.0 1.2 2.8 5.3 0.6
Stomach 57.4 77.2 37.8 29.6 42.4 18.4
Colon and rectum 56.5 66.8 46.3 28.7 37.0 21.4
Liver 30.4 45.1 15.8 15.6 25.0 7.1
Gallbladderb) 14.4 15.2 13.6 6.5 8.0 5.3
Pancreas 15.8 16.2 15.3 7.6 8.8 6.6
Larynx 2.4 4.5 0.3 1.2 2.4 0.1
Lung 58.4 79.4 37.4 27.7 41.7 16.9
Breast 48.6 0.4 96.5 30.4 0.3 60.5
Cervix uteri 6.4 - 12.7 4.0 - 8.0
Corpus uteri 6.4 - 12.8 4.0 - 7.9
Ovary 5.6 - 11.2 3.5 - 7.0
Prostate 32.7 65.6 - 15.5 34.3 -
Testis 0.6 1.3 - 0.6 1.2 -
Kidney 11.7 16.2 7.3 6.8 9.8 4.1
Bladder 9.5 15.6 3.5 4.4 8.2 1.4
Brain and CNS 3.9 4.2 3.5 2.9 3.2 2.6
Thyroid 59.8 29.3 90.0 42.9 21.0 65.6
Hodgkin lymphoma 0.6 0.7 0.5 0.5 0.6 0.4
Non-Hodgkin lymphoma 10.5 12.2 8.8 6.3 7.8 5.0
Multiple myeloma 3.6 3.9 3.2 1.8 2.1 1.5
Leukemia 7.3 8.2 6.3 5.6 6.7 4.7
Other and ill-defined 40.4 40.7 40.1 21.9 24.3 20.0

CNS, central nervous system.

a) Age-adjusted using the Segi’s world standard population,

b) Includes the gallbladder and other/unspecified parts of the biliary tract.

Table 3
The top 10 leading causes of death in Korea, 2019
Rank Cause of death No. of deaths Percentage of all deaths Age-standardized death rate per 100,000a)
All causes 295,039 100.0 254.4
1 Cancer 81,203 27.5 72.2
2 Heart disease 31,030 10.5 24.6
3 Cerebrovascular disease 21,586 7.3 16.9
4 Pneumonia 23,168 7.9 16.4
5 Intentional self-harm (suicide) 13,799 4.7 18.4
6 Diabetes mellitus 8,102 2.7 6.4
7 Disease of liver 6,496 2.2 6.8
8 Chronic lower respiratory diseases 6,176 2.1 4.4
9 Hypertensive diseases 5,631 1.9 3.9
10 Transport accidents 4,221 1.4 5.0
Others 93,698 31.8 79.5

Source: Mortality Data, 2019, Statistics Korea [1].

a) Age-adjusted using the Segi’s world standard population.

Table 4
Crude and age-standardized cancer mortality rates by sex in Korea, 2019
Site/Type Crude mortality rate per 100,000 Age-standardized mortality rate per 100,000a)
Both sexes Men Women Both sexes Men Women
All sites 158.2 196.3 120.2 72.2 103.6 48.7
Lip, oral cavity, and pharynx 2.5 3.9 1.2 1.2 2.1 0.5
Esophagus 3.0 5.6 0.5 1.4 2.9 0.2
Stomach 14.9 19.4 10.4 6.7 10.3 4.0
Colon and rectum 17.3 19.6 15.0 7.6 10.3 5.4
Liver 20.6 30.4 10.9 9.9 16.4 4.2
Gallbladderb) 9.7 10.0 9.4 4.1 5.1 3.2
Pancreas 12.5 13.4 11.6 5.6 7.1 4.4
Larynx 0.6 1.1 0.1 0.3 0.6 0.0
Lung 36.2 53.5 19.0 15.6 27.1 7.0
Breast 5.1 0.1 10.2 2.9 0.0 5.5
Cervix uteri 1.7 - 3.5 0.9 - 1.7
Corpus uteri 0.7 - 1.4 0.4 - 0.7
Ovary 2.4 - 4.8 1.2 - 2.4
Prostate 4.0 8.0 - 1.5 4.0 -
Testis 0.0 0.1 - 0.0 0.1 -
Kidney 1.9 2.6 1.2 0.9 1.4 0.4
Bladder 3.0 4.6 1.5 1.2 2.3 0.4
Brain and CNS 2.8 3.0 2.6 1.7 2.0 1.4
Thyroid 0.7 0.4 1.0 0.3 0.2 0.3
Hodgkin lymphoma 0.1 0.1 0.1 0.1 0.1 0.0
Non-Hodgkin lymphoma 3.6 4.2 3.0 1.7 2.3 1.2
Multiple myeloma 1.9 2.1 1.7 0.8 1.0 0.6
Leukemia 3.7 4.5 3.0 2.1 2.8 1.5
Other and ill-defined 9.1 10.0 8.3 4.3 5.6 3.3

CNS, central nervous system.

a) Age-adjusted using the world standard population,

b) Includes the gallbladder and other/unspecified parts of the biliary tract.

Table 5
Trends in cancer incidence and mortality rates from 1999 to 2019 in Korea, both sexes
Site/Type Incidence Mortality
1999 2019 Trend 1 Trend 2 Trend 3 1999 2019 Trend 1 Trend 2 Trend 3
Years APC Years APC Years APC Years APC Years APC Years APC
All sites 212.1 275.4 1999–2012 3.3a) 2012–2015 −5.3a) 2015–2019 1.1 115.1 72.2 1999–2002 0.9 2002–2013 −2.7a) 2013–2019 −3.3a)
Lip, oral cavity, and pharynx 3.6 4.3 1999–2019 0.7a) - - - - 1.1 1.2 1999–2019 −1.8a) - - - -
Esophagus 4.1 2.8 1999–2017 −2.2a) 2017–2019 1.8 - - 3.1 1.4 1999–2019 −4.43a) - - - -
Stomach 43.6 30.4 1999–2011 −0.2 2011–2018 −4.6a) - - 23.8 7.1 1999–2002 −2.6a) 2002–2010 −6.2a) 2010–2018 −7.4a)
Colon and rectum 20.5 28.7 1999–2006 7.3a) 2006–2011 2.9a) 2011–2019 4.0a) 7.8 7.6 1999–2003 6.4a) 2003–2012 −0.5 2012–2019 −3.6a)
Liver 27.9 15.6 1999–2009 −1.6a) 2009–2019 −4.1a) - - 20.6 9.9 1999–2002 0.6 2002–2014 −3.7a) 2014–2019 −6.1a)
Gallbladderb) 6.5 6.5 1999–2004 1.5 2004–2019 −0.4a) - - 5.2 4.1 1999–2001 7.6 2001–2014 −2.8a) 2014–2019 0.0
Pancreas 5.6 7.6 1999–2019 1.5a) - - - - 5.5 5.6 1999–2019 0.1 - - - -
Larynx 2.4 1.2 1999–2019 −3.5a) - - - - 1.6 0.3 1999–2005 −8.1a) 2005–2008 −15.5a) 2008–2019 −7.2a)
Lung 28.5 27.7 1999–2011 0.1 2011–2015 −1.4a) 2015–2019 0.6 22.5 15.6 1999–2001 3.8 2001–2014 −2.0a) 2014–2019 −3.9a)
Breast 11.0 30.4 1999–2007 6.4a) 2007–2019 4.4a) - - 2.3 2.9 1999–2004 2.9a) 2004–2019 0.8a) - -
Cervix uteri 8.6 4.0 1999–2007 −4.7a) 2007–2019 −3.0a) - - 1.4 0.9 1999–2003 10.1a) 2003–2008 −7.2a) 2008–2019 −4.0a)
Corpus uteri 1.4 4.0 1999–2019 5.1a) - - - - 0.1 0.4 1999–2003 36.0a) 2003–2019 2.4a) - -
Ovary 2.7 3.5 1999–2019 1.7a) - - - - 0.9 1.2 1999–2019 0.6a) - - - -
Prostate 3.1 15.5 1999–2009 14.9a) 2009–2015 0.5 2015–2019 7.3a) 0.9 1.5 1999–2002 15.3a) 2002–2011 1.6a) 2011–2019 −1.4a)
Testis 0.3 0.6 1999–2019 4.7a) - - - - 0.0 0.0 1999–2019 −2.1a) - - - -
Kidney 3.0 6.8 1999–2009 6.3a) 2009–2019 2.3a) - - 1.1 0.9 1999–2016 −0.1 2016–2019 −6.6a) - -
Bladder 4.7 4.4 1999–2004 1.8a) 2004–2019 −1.0a) - - 1.3 1.2 1999–2002 9.3a) 2002–2005 −6.1 2005–2019 −1.5a)
Brain and CNS 2.9 2.9 1999–2019 0.2 - - - 1.9 1.7 1999–2003 4.1a) 2003–2008 −4.4a) 2008–2019 −0.7a)
Thyroid 6.5 42.9 1999–2011 22.5a) 2011–2016 −12.3a) 2016–2019 6.2 0.4 0.3 1999–2003 7.5a) 2003–2019 −4.6a) - -
Hodgkin lymphoma 0.3 0.5 1999–2011 4.9a) 2011–2019 1.3 - - 0.0 0.1 1999–2004 23.7a) 2004–2019 −2.1a) - -
Non-Hodgkin lymphoma 4.3 6.3 1999–2019 2.3a) - - - - 2.1 1.7 1999–2019 −1.1a) - - - -
Multiple myeloma 1.0 1.8 1999–2012 3.7a) 2012–2019 1.2a) - - 0.6 0.8 1999–2003 12.7a) 2003–2016 0.9 2016–2019 −7.0a)
Leukemia 4.7 5.6 1999–2019 0.9a) - - - - 2.9 2.1 1999–2019 −1.8a) - - - -
Other and ill-defined 15.0 21.9 1999–2001 −0.9 2001–2007 3.7a) 2007–2019 1.8a) 7.8 4.3 1999–2019 −2.8a) - - - -

APC was calculated using age-standardized incidence data based on the Segi’s world standard population. APC, annual percentage change; CNS, central nervous system.

a) Significantly different from zero (p < 0.05),

b) Includes the gallbladder and other/unspecified parts of the biliary tract.

Table 6
Trends in the 5-year relative survival rates (%) by sex and year of diagnosis from 1993 to 2019 in Korea
Site/Type Both sexes Men Women
1993–1995 1996–2000 2001–2005 2006–2010 2011–2015 2015–2019 Changea) 1993–1995 1996–2000 2001–2005 2006–2010 2011–2015 2015–2019 Changea) 1993–1995 1996–2000 2001–2005 2006–2010 2011–2015 2015–2019 Changea)
All sites 42.9 45.2 54.1 65.5 70.7 70.7 27.8 33.2 36.3 45.6 56.9 63.1 64.5 31.3 55.2 56.4 64.3 74.4 78.3 77.3 22.1
All sites excluding thyroid 41.2 43.4 50.8 59.0 64.2 66.5 25.3 32.7 35.8 44.7 54.6 60.3 62.4 29.7 52.6 53.5 59.1 65.0 69.4 71.5 19.0
Lip, oral cavity, and pharynx 42.2 47.4 54.5 61.1 65.4 68.8 26.6 36.6 41.7 49.6 56.9 61.8 65.9 29.3 59.4 64.5 68.1 72.1 74.5 76.2 16.8
Esophagus 14.0 15.7 21.6 30.0 36.5 40.9 26.9 13.0 14.8 20.8 29.3 36.2 40.6 27.6 25.0 25.9 29.8 37.3 39.6 43.4 18.4
Stomach 43.9 47.3 58.0 68.4 75.9 77.5 33.6 44.0 47.6 58.7 69.1 76.8 78.3 34.3 43.7 46.8 56.6 67.0 74.0 75.8 32.1
Colon and rectum 56.2 58.9 66.9 73.9 76.1 74.3 18.1 56.6 59.8 68.8 75.8 77.8 75.5 18.9 55.7 57.7 64.4 71.1 73.6 72.6 16.9
Liver 11.8 14.1 20.5 28.3 34.4 37.7 25.9 10.8 13.8 20.4 28.3 34.9 38.3 27.5 15.1 15.1 20.9 28.3 32.8 35.8 20.7
Gallbladderb) 18.7 20.7 23.1 26.9 28.7 28.5 9.8 18.0 21.1 23.5 27.8 29.5 28.8 10.8 19.3 20.3 22.7 26.0 28.0 28.1 8.8
Pancreas 10.6 8.7 8.4 8.6 10.8 13.9 3.3 10.0 8.3 8.4 8.3 10.3 13.0 3.0 11.5 9.3 8.4 8.8 11.5 14.9 3.4
Larynx 61.6 63.3 66.5 73.2 75.3 80.4 18.8 62.2 63.7 67.1 73.5 75.7 80.5 18.3 56.3 58.9 58.7 68.0 69.1 78.9 22.6
Lung 12.5 13.6 16.6 20.3 27.6 34.7 22.2 11.6 12.4 15.3 18.0 23.3 28.9 17.3 15.8 17.5 20.2 26.0 37.4 47.4 31.6
Breast 79.2 83.6 88.7 91.2 92.8 93.6 14.4 77.1 84.3 87.5 89.9 90.8 93.3 16.2 79.3 83.6 88.7 91.2 92.8 93.6 14.3
Cervix uteri 78.3 80.3 81.5 80.7 80.3 80.5 2.2 - - - - - - - 78.3 80.3 81.5 80.7 80.3 80.5 2.2
Corpus uteri 82.9 82.0 84.7 86.5 87.7 89.0 6.1 - - - - - - - 82.9 82.0 84.7 86.5 87.7 89.0 6.1
Ovary 60.1 59.4 61.7 61.3 64.8 64.5 4.4 - - - - - - - 60.1 59.4 61.7 61.3 64.8 64.5 4.4
Prostate 59.1 69.4 81.0 92.0 94.2 94.4 35.3 59.1 69.4 81.0 92.0 94.2 94.4 35.3 - - - - - - -
Testis 87.4 90.4 90.7 93.2 94.9 95.0 7.6 87.4 90.4 90.7 93.2 94.9 95.0 7.6 - - - - - - -
Kidney 64.2 67.0 73.7 78.6 82.5 84.7 20.5 63.4 65.4 73.1 78.5 82.1 84.7 21.3 65.8 70.3 74.9 79.0 83.4 84.8 19.0
Bladder 70.7 73.6 76.0 77.3 76.4 76.5 5.8 71.6 75.1 77.8 79.3 78.4 78.1 6.5 67.2 67.2 69.1 69.2 68.5 70.0 2.8
Brain and CNS 40.4 39.9 41.0 42.9 41.7 41.4 1.0 39.1 38.7 40.3 41.4 40.4 40.0 0.9 42.3 41.4 41.8 44.6 43.3 43.0 0.7
Thyroid 94.5 95.0 98.4 100.0 100.2 100.0 5.5 87.9 89.7 96.0 100.2 100.6 100.3 12.4 95.7 96.0 98.7 99.9 100.1 99.9 4.2
Hodgkin lymphoma 70.2 71.9 76.7 81.1 82.3 85.3 15.1 69.4 69.3 74.7 80.8 81.8 84.5 15.1 71.5 77.3 80.7 81.6 83.3 86.5 15.0
Non-Hodgkin lymphoma 48.3 51.1 56.0 59.4 62.8 64.5 16.2 46.8 49.6 55.0 59.2 62.9 65.3 18.5 50.6 53.3 57.5 59.7 62.8 63.5 12.9
Multiple myeloma 23.7 21.0 29.7 34.9 41.5 49.1 25.4 23.2 19.1 29.9 35.1 41.1 49.7 26.5 24.1 23.3 29.5 34.7 42.1 48.6 24.5
Leukemia 27.5 34.3 42.0 47.7 52.0 54.5 27.0 27.3 33.3 41.8 46.9 52.2 54.2 26.9 27.8 35.5 42.2 48.7 51.7 55.0 27.2
Other and ill-defined 44.5 48.3 57.9 67.7 72.7 75.4 30.9 39.6 44.7 54.1 63.8 69.3 72.5 32.9 50.1 52.6 62.0 71.6 76.2 78.3 28.2

CNS, central nervous system.

a) Absolute percentage change in 5-year relative survival from 1993 to 1995 and 2015 to 2019,

b) Includes the gallbladder and other/unspecified parts of the biliary tract.

Table 7
Crude and age-standardized rates of cancer prevalence by sex on January 1, 2020 in Korea
Site/Type Crude prevalence rate per 100,000a) Age-standardized prevalence rate per 100,000b)
Both sexes Men Women Both sexes Men Women
All sites 4,183.1 3,684.3 4,679.7 2,305.1 2,081.4 2,612.8
Lip, oral cavity, and pharynx 57.5 77.0 38.1 32.2 44.6 21.2
Esophagus 23.5 42.1 5.1 11.4 22.2 2.4
Stomach 621.3 822.7 420.8 306.6 441.6 194.2
Colon and rectum 544.9 648.1 442.1 266.0 349.9 197.2
Liver 146.6 220.3 73.2 77.5 123.3 35.8
Gallbladderc) 49.7 51.5 47.9 23.0 27.1 19.7
Pancreas 29.1 29.5 28.8 15.3 16.5 14.4
Larynx 23.2 43.8 2.7 11.0 23.0 1.2
Lung 200.8 242.5 159.4 98.0 128.6 74.4
Breast 504.7 3.7 1,003.5 291.5 2.0 574.2
Cervix uteri 114.9 0.0 229.3 65.1 - 127.6
Corpus uteri 60.3 0.0 120.3 34.8 - 68.6
Ovary 47.3 0.0 94.3 29.7 - 59.2
Prostate 212.1 425.1 0.0 91.8 213.8 -
Testis 7.9 15.8 0.0 7.0 13.7 -
Kidney 98.7 133.8 63.8 55.3 78.5 34.2
Bladder 77.8 127.3 28.6 35.7 66.8 11.5
Brain and CNS 25.2 26.0 24.4 20.7 21.9 19.4
Thyroid 900.2 330.2 1,467.6 563.7 212.3 913.4
Hodgkin lymphoma 6.7 8.3 5.1 5.4 6.4 4.3
Non-Hodgkin lymphoma 74.0 84.1 63.8 48.1 57.6 39.1
Multiple myeloma 15.1 15.9 14.3 7.6 8.7 6.7
Leukemia 49.7 55.4 44.2 44.0 49.3 38.6
Other and ill-defined 291.9 281.4 302.4 163.7 173.7 155.4

CNS, central nervous system.

a) Crude prevalence rate: number of prevalent cases divided by the corresponding person-years of observation. Prevalent cases were defined as patients who were diagnosed between January 1, 1999 and December 31, 2019 and who were alive on January 1, 2020. Multiple primary cancer cases were counted multiple times,

b) Age-adjusted using the Segi's world standard opulation

c) Includes the gallbladder and other/unspecified parts of the biliary tract

  • 1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Pineros M, et al. Global cancer observatory: cancer today [Internet]. Lyon: International Agency for Research on Cancer; 2020. [cited 2022 Feb 13]. Available from: https://gco.iarc.fr/today
  • 2. Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127:3029–30. ArticlePubMed
  • 3. Statistics Korea [Internet]. Daejeon: Statistics Korea; 2020. [cited 2022 Feb 13]. Available from: http://kosis.kr
  • 4. Shin HR, Won YJ, Jung KW, Kong HJ, Yim SH, Lee JK, et al. Nationwide cancer incidence in Korea, 1999~2001; first result using the national cancer incidence database. Cancer Res Treat. 2005;37:325–31. ArticlePubMedPMC
  • 5. Ajiki W, Tsukuma H, Oshima A. Index for evaluating completeness of registration in population-based cancer registries and estimation of registration rate at the Osaka Cancer Registry between 1966 and 1992 using this index. Nihon Koshu Eisei Zasshi. 1998;45:1011–7. PubMed
  • 6. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al. International classification of diseases for oncology. 3rd ed 1st rev. Geneva: World Health Organization; 2013.
  • 7. World Health Organization. International statistical classification of diseases and related health problems. 10th rev. Geneva: World Health Organization; 1994.
  • 8. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Pineros M, et al. Global cancer observatory: cancer today – data and methods [Internet]. Lyon: International Agency for Research on Cancer; 2020. [cited 2022 Feb 13]. Available from: https://gco.iarc.fr/today/data-sources-methods
  • 9. Cancer incidence in five continents, XI Chapter 3 Classification and coding [Internet]. Lyon: International Agency for Research on Cancer; 2020. [cited 2022 Feb 13]. Available from: http://ci5.iarc.fr/CI5-XI/Pages/Chapter3.aspx
  • 10. Young JL Jr, Roffers SD, Ries LA, Fritz AG, Hurlbut AA. SEER summary staging manual 2000: codes and coding instructions. National Cancer Institute NIH Pub No 01-4969. Bethesda, MD: National Cancer Institute; 2001.
  • 11. Cancer incidence in five continents, Vol XI Chapter 7 Age standardization [Internet]. Lyon: International Agency for Research on Cancer; 2020. [cited 2022 Feb 13]. Available from: http://ci5.iarc.fr/CI5-XI/Pages/Chapter7.aspx
  • 12. Segi M. Cancer mortality for selected sites in 24 countries 1950–1957. Sendai: Tohoku University School of Medicine; 1960.
  • 13. Surveillance Research Program Joinpoint Regression Program, version 4801 [Internet]. Bethesda, MD: Surveillance Research Program, National Cancer Institute; 2020. [cited 2022 Feb 13]. Available from: https://surveillance.cancer.gov/join-point/
  • 14. Ederer F, Heise H. Instructions to IBM 650 programmers in processing survival computations. Methodological note, No 10. Bethesda, MD: National Cancer Institute; 1959.
  • 15. Paul Dickman [Internet]. Stockholm: PaulDickman.com; 2016. [cited 2022 Feb 13]. Available from: http://www.pauldickman.com

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  
    • Factors Associated With Quality of Life Among Posttreatment Cancer Survivors in Korea
      Soo Hyun Kim, Yu Hyeon Choe, Jingyeong Choi, Ji Young Park, Eun Yi
      Cancer Nursing.2025; 48(1): E47.     CrossRef
    • Risk factors and incidence of oral tumors: Findings from a longitudinal population‐based study
      Young‐Taek Kim, Min‐Jin Kang, Bo‐Ah Lee, Sang‐Hoon Kang, Reuben H. Kim
      Oral Diseases.2025; 31(3): 846.     CrossRef
    • F-18 FDG PET/CT Clinical Service Trends in Korea from 2018 to 2022: A National Surveillance Study
      Jaesun Yoon, Heejin Kim, Do Hyun Woo, Seung Yeop Chae, Ji Heui Lee, Inki Lee, Ilhan Lim, Byung Il Kim, Chang Woon Choi, Byung Hyung Byun
      Nuclear Medicine and Molecular Imaging.2025; 59(2): 117.     CrossRef
    • Survival feature and trend of female breast cancer: A comprehensive review of survival analysis from cancer registration data
      Dan-Dan Tang, Zhuo-Jun Ye, Wan-Wan Liu, Jing Wu, Jing-Yu Tan, Yan Zhang, Qun Xu, Yong-Bing Xiang
      The Breast.2025; 79: 103862.     CrossRef
    • Survey of the Actual Practices Used for Endoscopic Removal of Colon Polyps in Korea: A Comparison with the Current Guidelines
      Jeongseok Kim, Tae-Geun Gweon, Min Seob Kwak, Su Young Kim, Seong Jung Kim, Hyun Gun Kim, Sung Noh Hong, Eun Sun Kim, Chang Mo Moon, Dae Seong Myung, Dong-Hoon Baek, Shin Ju Oh, Hyun Jung Lee, Ji Young Lee, Yunho Jung, Jaeyoung Chun, Dong-Hoon Yang, Eun R
      Gut and Liver.2025; 19(1): 77.     CrossRef
    • Epidemiology and survival analysis according to the histologic subtype of pancreatic cancer: a population-based cohort study
      Hyeong Min Park, Mee Joo Kang, Sang-Jae Park, Kyu-Won Jung, Sung-Sik Han
      Annals of Surgical Treatment and Research.2025; 108(1): 20.     CrossRef
    • Cancer incidence and the influence of immunosuppressive agents in Korean patients with systemic lupus erythematosus: a retrospective cohort study
      Soo-Kyung Cho, Jung-Yong Han, Yena Jeon, Seung-Hun You, Sun-Young Jung, Eun Jin Jang, Yoon-Kyoung Sung
      Arthritis Research & Therapy.2025;[Epub]     CrossRef
    • Recent 5‑year trends in biliary tract cancer survival rates: An analytical big data survey
      Ji Yoon Lee, Ju Won Kim
      Medicine International.2025;[Epub]     CrossRef
    • Effects of Anticancer Therapy on Osteoporosis in Breast Cancer Patients: A Nationwide Study Using Data from the National Health Insurance Service-National Health Information Database
      Minji Kwon, Bo-Hyung Kim, Sun Young Min, Sumin Chae
      Journal of Clinical Medicine.2025; 14(3): 732.     CrossRef
    • Risk of Cancers According to the Use of Biological Agents in Patients With Radiographic Axial Spondyloarthritis
      Oh Chan Kwon, Hye Sun Lee, Juyeon Yang, Min-Chan Park
      JCR: Journal of Clinical Rheumatology.2025; 31(3): e13.     CrossRef
    • Risk of second primary malignancies among survivors of cutaneous melanoma: A nationwide population-based study in the Republic of Korea
      Joon Min Jung, Do Hyung Kim, Ye-Jee Kim, Ik Jun Moon, Woo Jin Lee, Sung Eun Chang, Mi Woo Lee, Chong Hyun Won
      Scientific Reports.2025;[Epub]     CrossRef
    • A comparative study of health behaviors in adult male cancer survivors and the general male population in Korea: from the Korea national health and nutrition examination survey VII-VIII (2016–2021)
      Hyein Jung, Yoonjoo Choi, Byungmi Kim
      Supportive Care in Cancer.2025;[Epub]     CrossRef
    • Association between resting heart rate and prognosis in patients with gastric cancer
      Dong Hoon Lee, Dong-Hyuk Park, Tae Ho Lee, Edward L. Giovannucci, Sung Hyun Park, Minah Cho, Yoo Min Kim, Woo Jin Hyung, Justin Y. Jeon, Hyoung-Il Kim
      Scientific Reports.2025;[Epub]     CrossRef
    • Global trends in gallbladder cancer survival: A 30-year analysis of cancer registry data
      Yu-Xuan Xiao, Jun Chen, Zhuo-Ying Li, Yi-Xin Zou, Xiao-Hui Zhou, Wei Zhang, Hong-Lan Li, Evelyne Y. Bischof, Yong-Bing Xiang
      Heliyon.2025; 11(4): e42853.     CrossRef
    • Preliminary reports of lung cancer screening with low-dose computed tomography: a nationwide performance on the Korean population in 2019–2020
      Horim A. Hwang, Dong Jun Kim, Nan-He Yoon, Jae Kwan Jun, Mina Suh, Sunhwa Lee, Seongju Kim, Seung Eun Jung, Hooyeon Lee
      European Radiology.2025;[Epub]     CrossRef
    • Treatment patterns and clinical outcomes for multiple myeloma in Korean patients: a database study
      Junghyun Yoon, Jongheon Jung, Boyoung Park, Eunyoung Lee, YoungJu Park, Soomin Yoon, Hyeon-Seok Eom
      BMC Cancer.2025;[Epub]     CrossRef
    • Cancer care and cancer mortality: regional analysis in the context of Russia
      Yu. V. Samsonov, A. A. Kostin
      Siberian journal of oncology.2025; 24(2): 16.     CrossRef
    • Intraoperative Nerve Monitoring in Thyroid Surgery: A Comprehensive Review of Technical Principles, Anesthetic Considerations, and Clinical Applications
      Ji-Yoon Jung
      Journal of Clinical Medicine.2025; 14(9): 3259.     CrossRef
    • Role of Artificial Intelligence in Improving Quality of Colonoscopy
      Ji Hyun Kim, Sung Chul Park, Hyun-Soo Kim
      The Korean Journal of Gastroenterology.2025; 85(2): 137.     CrossRef
    • Effects of Pressure Hemostasis Band Application on Bleeding, Pain, and Discomfort after Bone Marrow Examination
      Jin Hee Jung, Bo-Eun Kim, Ji Sook Ju, Mi Ryu, So Young Choe, Jong Hee Choi, Soo-Mee Bang, Jeong-Ok Lee, Ji Yun Lee, Sang-A Kim
      Asian Oncology Nursing.2025; 25(1): 17.     CrossRef
    • Monte Carlo Simulation-Based ACR Phantom to Evaluate Performance of Digital Mammography Detector
      Yeji Kim, Seongwon Jeon, Hojin Kim, Yongsu Yoon
      Journal of Radiological Science and Technology.2025; 48(1): 39.     CrossRef
    • Conditional Relative Survival of Gallbladder Cancer: A Population-Based Study in a High-Incidence Asian Country from 1999 to 2021
      Mee Joo Kang, Johyun Ha, Sang-Jae Park, Hyeong Min Park, Kyu-Won Jung, Sung-Sik Han
      Annals of Surgical Oncology.2025;[Epub]     CrossRef
    • Incidence of Depression and Anxiety in Kidney Cancer Survivors: A Nationwide Population-Based Cohort Study
      Minji Jung, Mingyi Li, Eunjung Choo, Sukhyang Lee, David Spiegel, Michael Baiocchi, Zhengyi Deng, Jinhui Li, Marvin E. Langston, Melissa L. Bondy, Benjamin I. Chung
      Cancer Epidemiology, Biomarkers & Prevention.2025; 34(6): 1027.     CrossRef
    • Clarifying the misinterpretation of case-fatality rate as mortality in thyroid cancer studies
      Kyu-Won Jung, Eun Hye Park, Mee Joo Kang
      International Journal of Surgery.2025; 111(6): 4103.     CrossRef
    • Risk of Neurodevelopmental Disorders in the Offspring of Young Female Cancer Survivors
      Kyujin Choi, Jihye Heo, Soo-Young Oh, Jonghan Yu, Juyoung Sung, Insung Kim, Su-Min Jeong, Danbee Kang
      Journal of Autism and Developmental Disorders.2025;[Epub]     CrossRef
    • Radiological Assessment of Loss of Coolant Accident from Saeul Nuclear Power Plant
      Moses Oboo, Juyoul Kim
      Journal of Radiation Protection and Research.2025; 50(s1): S12.     CrossRef
    • The Effects of Coping Strategies Between Uncertainty and Quality of Life of Korean Women With Gynecological Cancer
      Eungil Ko, Yaelim Lee
      Advances in Nursing Science.2024; 47(3): E84.     CrossRef
    • Adherence of PARP inhibitor for frontline maintenance therapy in primary epithelial ovarian cancer: a cross-sectional survey
      Ji Hyun Kim, Yumi Lee, Da-Young Kim, Sinae Kim, Sang-Soo Seo, Sokbom Kang, Sang-Yoon Park, Myong Cheol Lim
      Journal of Gynecologic Oncology.2024;[Epub]     CrossRef
    • The association of diet-dependent acid load with colorectal cancer risk: a case–control study in Korea
      Tao Thi Tran, Madhawa Gunathilake, Jeonghee Lee, Jae Hwan Oh, Hee Jin Chang, Dae Kyung Sohn, Aesun Shin, Jeongseon Kim
      British Journal of Nutrition.2024; 131(2): 333.     CrossRef
    • Quantitative assessment of breast volume changes after whole-breast irradiation for breast cancer using breast auto-segmentation
      Tae Hoon Lee, Sang Hee Ahn, Kwangzoo Chung, Won Park, Won Kyung Cho, Nalee Kim, Tae Gyu Kim, Haeyoung Kim
      Breast Cancer Research and Treatment.2024; 203(2): 205.     CrossRef
    • Regularity of cervical cancer screening in Korea: analysis using national public data for 12 years
      Jong-Yeup Kim, Jeeyoung Hong, Juhee Yoon, Jinsol Park, Tae-Hyun Kim
      Journal of Gynecologic Oncology.2024;[Epub]     CrossRef
    • Dietary Isoflavone Intake and Breast Cancer Prognosis: A Prospective Analysis and Meta-Analysis
      Sihan Song, Jong-Ho Cheun, Hyeong-Gon Moon, Dong-Young Noh, So-Youn Jung, Eun Sook Lee, Zisun Kim, Hyun Jo Youn, Jihyoung Cho, Young Bum Yoo, Shinyoung Jun, Hyojee Joung, Jung Eun Lee
      Nutrition and Cancer.2024; 76(1): 42.     CrossRef
    • Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer (KCSG-BR15-17): A randomized, open-label, multicenter, phase II trial
      Dae-Won Lee, Kyung Hae Jung, Kyung-Hun Lee, Yeon Hee Park, Keun Seok Lee, Joohyuk Sohn, Hee Kyung Ahn, Jae Ho Jeong, Su-Jin Koh, Jee Hyun Kim, Han Jo Kim, Kyoung Eun Lee, Hee-Jun Kim, Yae-Won Yang, Kyong Hwa Park, Jieun Lee, Hye Sung Won, Tae-Yong Kim, Se
      European Journal of Cancer.2024; 197: 113456.     CrossRef
    • Maintaining Healthy Fasting Blood Glucose Levels Is Important for Korean Cancer Survivors
      Jaehoon Chung
      CardioMetabolic Syndrome Journal.2024; 4(1): 20.     CrossRef
    • Subsite‐specific trends in mid‐ and long‐term survival for head and neck cancer patients in Japan: A population‐based study
      Hiroshi Tsuge, Daisuke Kawakita, Yukari Taniyama, Isao Oze, Yuriko N. Koyanagi, Megumi Hori, Kayo Nakata, Hiromi Sugiyama, Isao Miyashiro, Izumi Oki, Yoshikazu Nishino, Kota Katanoda, Yuri Ito, Akiko Shibata, Tomohiro Matsuda, Shinichi Iwasaki, Keitaro Ma
      Cancer Science.2024; 115(2): 623.     CrossRef
    • Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset
      Ki Hyeong Lee, Byoung Chul Cho, Myung-Ju Ahn, Yun-Gyoo Lee, Youngjoo Lee, Jong-Seok Lee, Joo-Hang Kim, Young Joo Min, Gyeong-Won Lee, Sung Sook Lee, Kyung-Hee Lee, Yoon Ho Ko, Byoung Yong Shim, Sang-We Kim, Sang Won Shin, Jin-Hyuk Choi, Dong-Wan Kim, Eun
      Cancer Research and Treatment.2024; 56(1): 48.     CrossRef
    • Conditional Relative Survival of Exocrine Pancreatic Cancer: A Population-Based Study
      Mee Joo Kang, Johyun Ha, Hyeong Min Park, Sang-Jae Park, Kyu-Won Jung, Sung-Sik Han
      Annals of Surgical Oncology.2024; 31(2): 1178.     CrossRef
    • Trends in the incidence and survival outcomes of endometrial cancer in Korea: a nationwide population-based cohort study
      Seung-Hyuk Shim, Jiwon Lim, Ji Hyun Kim, Yeon Jee Lee, Hyeong In Ha, Myong Cheol Lim, Young-Joo Won
      Journal of Gynecologic Oncology.2024;[Epub]     CrossRef
    • Twenty-two-year incidence trend of urological cancers in the Republic of Korea: 1999–2020
      Seunghyeon Cho, Won-Ju Park
      Investigative and Clinical Urology.2024; 65(1): 23.     CrossRef
    • Efficacy of preoperative lymphoscintigraphy in predicting surgical outcomes of lymphaticovenous anastomosis in lower extremity lymphedema: Clinical correlations in gynecological cancer-related lymphedema
      Min Young Yoo, Kyong-Je Woo, Seo Young Kang, Byung Seok Moon, Bom Sahn Kim, Hai-Jeon Yoon, Andrea Giannini
      PLOS ONE.2024; 19(1): e0296466.     CrossRef
    • Analysis of distress in patients undergoing radical prostatectomy: A multicenter prospective study
      Duk Yoon Kim, Jae Hyun Ryu, Tag Keun Yoo, Yun Beom Kim, Tae Young Jung, Woo Jin Ko, Eun Kyoung Yang
      Investigative and Clinical Urology.2024; 65(1): 40.     CrossRef
    • Potential role of Fibrosis‐4 score in hepatocellular carcinoma screening: The Kangbuk Samsung Health Study
      Sujeong Shin, Won Sohn, Yoosoo Chang, Yoosun Cho, Min‐Jung Kwon, Sarah H. Wild, Christopher D. Byrne, Seungho Ryu
      Hepatology Research.2024; 54(6): 551.     CrossRef
    • Comparison of the Prognosis of Upper-Third Gastric Cancer With That of Middle and Lower-Third Gastric Cancer
      Ji Yeon Park, Eun Ji Kim, Jae Yeong Yang, Ki Bum Park, Oh Kyoung Kwon
      Journal of Gastric Cancer.2024; 24(2): 159.     CrossRef
    • Genomic and Transcriptomic Characterization of Gastric Cancer with Bone Metastasis
      Sujin Oh, Soo Kyung Nam, Keun-Wook Lee, Hye Seung Lee, Yujun Park, Yoonjin Kwak, Kyu Sang Lee, Ji-Won Kim, Jin Won Kim, Minsu Kang, Young Suk Park, Sang-Hoon Ahn, Yun-Suhk Suh, Do Joong Park, Hyung Ho Kim
      Cancer Research and Treatment.2024; 56(1): 219.     CrossRef
    • Long-Term Outcomes of Colon Conduits in Surgery for Primary Esophageal Cancer: A Propensity Score-Matched Comparison to Gastric Conduits
      Jae Hoon Kim, Jae Kwang Yun, Chan Wook Kim, Hyeong Ryul Kim, Yong-Hee Kim
      Journal of Chest Surgery.2024; 57(1): 53.     CrossRef
    • Injectable Mesocellular Foam Silica Microparticles with a Dual Role of Cell‐Recruiting Scaffolds and Intracellular Delivery Vehicles for Enhanced Cancer Vaccine
      Jihye Im, Youngjin Choi, Thanh Loc Nguyen, Min Kyung Kim, Jaeyun Kim
      Advanced Functional Materials.2024;[Epub]     CrossRef
    • Pretreatment Interstitial Lung Abnormalities Detected on Abdominal Computed Tomography Scans in Prostate Cancer Patients
      Hyun Jin Kim, Won Gi Jeong, Jeong Yeop Lee, Hyo-Jae Lee, Byung Chan Lee, Hyo Soon Lim, Yun-Hyeon Kim
      Journal of Computer Assisted Tomography.2024; 48(3): 406.     CrossRef
    • Perinatal and childhood outcomes of children born to female cancer survivors in South Korea
      Ju Hyun Jin, Tae Mi Youk, Jisun Yun, Ja Yoon Heo
      Scientific Reports.2024;[Epub]     CrossRef
    • Changes in the Epidemiologic Pattern of Primary CNS Tumors in Response to the Aging Population: An Updated Nationwide Cancer Registry Data in the Republic of Korea
      Yoon Hwan Byun, Johyun Ha, Ho Kang, Chul-Kee Park, Kyu-Won Jung, Heon Yoo
      JCO Global Oncology.2024;[Epub]     CrossRef
    • Efficacy and Toxicity of Palliative Chemotherapy in Elderly Patients With Advanced Pancreatic Cancer
      Han Taek Jeong, Ho Gak Kim, Jimin Han
      Pancreas.2024; 53(3): e268.     CrossRef
    • Tubulointerstitial nephritis antigen-like 1 from cancer-associated fibroblasts contribute to the progression of diffuse-type gastric cancers through the interaction with integrin β1
      Dagyeong Lee, In-Hye Ham, Hye Jeong Oh, Dong Min Lee, Jung Hwan Yoon, Sang-Yong Son, Tae-Min Kim, Jae-Young Kim, Sang-Uk Han, Hoon Hur
      Journal of Translational Medicine.2024;[Epub]     CrossRef
    • The Association of Low-Carbohydrate Diet and HECTD4 rs11066280 Polymorphism with Risk of Colorectal Cancer: A Case-Control Study in Korea
      Tao Thi Tran, Madhawa Gunathilake, Jeonghee Lee, Jae Hwan Oh, Hee Jin Chang, Dae Kyung Sohn, Aesun Shin, Jeongseon Kim
      Current Developments in Nutrition.2024; 8(3): 102127.     CrossRef
    • Assessing visibility and bone changes of spinal metastases in CT scans: a comprehensive analysis across diverse cancer types
      Jung Oh Lee, Dong Hyun Kim, Hee-Dong Chae, Eugene Lee, Ji Hee Kang, Ji Hyun Lee, Hyo Jin Kim, Jiwoon Seo, Jee Won Chai
      Skeletal Radiology.2024; 53(8): 1553.     CrossRef
    • Living experiences of older patients with cancer amid the COVID-19 pandemic: A phenomenological study
      Yong Hwan Hyeon, Kyoung Ja Moon
      Journal of Korean Gerontological Nursing.2024; 26(1): 54.     CrossRef
    • Evaluation of clinical usefulness of HPV-16 and HPV-18 genotyping for cervical cancer screening
      Eun Hye Cho, Min-Seung Park, Hee-Yeon Woo, Hyosoon Park, Min-Jung Kwon
      Journal of Gynecologic Oncology.2024;[Epub]     CrossRef
    • Assessment and validation of glottic motion using cone-beam CT and real-time cine MRI
      Seok-Joo Chun, Jaeman Son, Seonghee Kang, Chang Heon Choi, Jung-in Kim, Young-Il Kim, Joo Ho Lee, Jin Ho Kim, Hong-Gyun Wu
      Strahlentherapie und Onkologie.2024; 200(5): 418.     CrossRef
    • Risk of Subsequent Primary Cancers Among Adult-Onset 5-Year Cancer Survivors in South Korea: Retrospective Cohort Study
      Yoon Young Choi, Myeongjee Lee, Eun Hwa Kim, Jae Eun Lee, Inkyung Jung, Jae-Ho Cheong
      JMIR Public Health and Surveillance.2024; 10: e48380.     CrossRef
    • Glycemic traits and colorectal cancer survival in a cohort of South Korean patients: A Mendelian randomization analysis
      So Yon Jun, Sooyoung Cho, Min Jung Kim, Ji Won Park, Seung‐Bum Ryoo, Seung Yong Jeong, Kyu Joo Park, Aesun Shin
      Cancer Medicine.2024;[Epub]     CrossRef
    • Sex-specific associations of empirically derived dietary patterns with colorectal cancer risk in a Korean population: a case‒control study
      Minji Kim, Madhawa Gunathilake, Jeonghee Lee, Jae Hwan Oh, Hee Jin Chang, Dae Kyung Sohn, Aesun Shin, Jeongseon Kim
      Scientific Reports.2024;[Epub]     CrossRef
    • Risk prediction model for gastric cancer within 5 years in healthy Korean adults
      Hyungseok Oh, Sunwoo Cho, Jung Ah Lee, Seungho Ryu, Yoosoo Chang
      Gastric Cancer.2024; 27(4): 675.     CrossRef
    • Contents analysis of thyroid cancer-related information uploaded to YouTube by physicians in Korea: endorsing thyroid cancer screening, potentially leading to overdiagnosis
      EunKyo Kang, HyoRim Ju, Soojeong Kim, Juyoung Choi
      BMC Public Health.2024;[Epub]     CrossRef
    • Implication of Pre- and Post-radiotherapy ctDNA Dynamics in Patients with Residual Triple-Negative Breast Cancer at Surgery after Neoadjuvant Chemotherapy: Findings from a Prospective Observational Study
      Tae Hoon Lee, Haeyoung Kim, Yeon Jeong Kim, Woong-Yang Park, Won Park, Won Kyung Cho, Nalee Kim
      Cancer Research and Treatment.2024; 56(2): 531.     CrossRef
    • The interaction effect of dietary selenium intake and the IL10 rs1800871 polymorphism on the risk of colorectal cancer: a case–control study in Korea
      Tao Thi Tran, Madhawa Gunathilake, Jeonghee Lee, Jae Hwan Oh, Hee Jin Chang, Dae Kyung Sohn, Aesun Shin, Jeongseon Kim
      British Journal of Nutrition.2024; 131(12): 2039.     CrossRef
    • Monte Carlo Simulation-Based Mammographic Anti-Scatter Grids to Evaluate Performance of Digital Mammography Detector
      Yeji Kim, Hyejin Jo, Yongsu Yoon
      Journal of Radiological Science and Technology.2024; 47(1): 1.     CrossRef
    • Secondary hematological malignancies in patients with sarcoma: A single‑center retrospective study
      Yoon Jang, Hong Jeong, Chang-Bae Kong, Won Song, Wan Cho, Dae Jeon, Heyjin Kim, Sung Yang, Im Na, Hyo-Rak Lee, Hye Kang
      Oncology Letters.2024;[Epub]     CrossRef
    • Association between non-healing precancerous oral lesions and ulcers with tobacco smoking: A population-based study
      Olawale Olatunbosun Adamson, Olufemi Erinoso, Remilekun Oluwakuyide, Abiodun Amao, Olajumoke Effiom, Olalekan Micah Gbotolorun
      Oral Oncology Reports.2024; 10: 100428.     CrossRef
    • Comparative Study of Diabetes Knowledge, Attitudes, Family Support, Self-efficacy, and Self-management Behaviors Between Cancer Survivors With Diabetes and Diabetes Patients Without Cancer
      Eun Jeong Ko, Su Jung Lee
      Cancer Nursing.2024;[Epub]     CrossRef
    • Optimal Dietary Intake of Riboflavin Associated with Lower Risk of Cervical Cancer in Korea: Korean National Health and Nutrition Examination Survey 2010–2021
      Seon-Mi Lee, Aeran Seol, Hyun-Woong Cho, Kyung-Jin Min, Sanghoon Lee, Jin-Hwa Hong, Jae-Yun Song, Jae-Kwan Lee, Nak-Woo Lee
      Life.2024; 14(4): 529.     CrossRef
    • Sex differences of the association between handgrip strength and health-related quality of life among patients with cancer
      Jihye Kim, Yujin Kim, Jae Won Oh, San Lee
      Scientific Reports.2024;[Epub]     CrossRef
    • Elucidating immunological characteristics of the adenoma-carcinoma sequence in colorectal cancer patients in South Korea using a bioinformatics approach
      Jaeseung Song, Daeun Kim, Junghyun Jung, Eunyoung Choi, Yubin Lee, Yeonbin Jeong, Byungjo Lee, Sora Lee, Yujeong Shim, Youngtae Won, Hyeki Cho, Dong Kee Jang, Hyoun Woo Kang, Jong Wha J. Joo, Wonhee Jang
      Scientific Reports.2024;[Epub]     CrossRef
    • No Change in Complications Following Thyroidectomy Despite Increase in Thyroid Cancer Surgeries: A Meta-Regression Analysis
      Jun Sung Lee, Jin Seok Lee, Hyeok Jun Yun, Seok-Mo Kim, Hojin Chang, Yong Sang Lee, Juyeon Yang, Hye Sun Lee, Hang-Seok Chang
      Yonsei Medical Journal.2024; 65(6): 348.     CrossRef
    • Clinical significance of the advanced lung cancer inflammation index in patients with limited-stage small cell lung cancer treated with chemoradiotherapy
      Bo Mi Seo, Jiin Choi, Boksoon Chang, Bo-Guen Kim, Tai Sun Park, Hyun Lee, Ji-Yong Moon, Sang-Heon Kim, Tae-Hyung Kim, Seung-Jin Yoo, Hae Jin Park, Ho Joo Yoon, Jang Won Sohn, Seung Hyeun Lee, Dong Won Park
      Scientific Reports.2024;[Epub]     CrossRef
    • Comparative analysis of genetic testing utilization rates among people with and without disabilities in South Korea from 2016 to 2019, focusing on malignant neoplasms: A national population‐based study
      Gwanwook Bang, Minji Park, Jeong‐yeon Seon, So‐Youn Park
      Cancer Medicine.2024;[Epub]     CrossRef
    • Thyroid Cancer Incidence Among Korean Individuals: A Comparison of South Korea and the United States
      Dohun Kim, Guan Li, Peter K. Moon, Yifei Ma, Soohyun Sim, Sung Y. Park, Minkyung Oh, Uchechukwu C. Megwalu
      The Laryngoscope.2024; 134(9): 4156.     CrossRef
    • Risk Factors and Mortality Among Women With Interval Breast Cancer vs Screen-Detected Breast Cancer
      Huiyeon Song, Thi Xuan Mai Tran, Soyeoun Kim, Boyoung Park
      JAMA Network Open.2024; 7(5): e2411927.     CrossRef
    • Survival of Patients with Primary Brain Tumor: A Data Analysis of 10 Years
      Shristy Verma, Rishabha Malviya, Prerna Uniyal
      Current Pharmaceutical Design.2024; 30(15): 1129.     CrossRef
    • Neoadjuvant Cisplatin-Based Chemotherapy Followed by Selective Bladder Preservation Chemoradiotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder: Post Hoc Analysis of Two Prospective Studies
      Sung Wook Cho, Sung Hee Lim, Ghee Young Kwon, Chan Kyo Kim, Won Park, Hongryull Pyo, Jae Hoon Chung, Wan Song, Hyun Hwan Sung, Byong Chang Jeong, Se Hoon Park
      Cancer Research and Treatment.2024; 56(3): 893.     CrossRef
    • The risk for subsequent primary lung cancer after cervical carcinoma: A quantitative analysis based on 864,627 cases
      Sheng Gong, Gang Li, Dan Li, Yu Liu, Banggui Wu, Yan Wang
      PLOS ONE.2024; 19(6): e0305670.     CrossRef
    • Analysis of Aeromedical Consultation Related to Malignant Tumor of Korean Military Flight Crews
      Du Hyun Song
      The Korean Journal of Aerospace and Environmental Medicine.2024; 34(2): 40.     CrossRef
    • Seasonal influences on the efficacy of anti–programmed cell death (ligand) 1 inhibitors in lung cancer
      Hyunsoon Cho, Hoejun Kwon, Se Hyun Kim, Hyung‐Min Ahn, Beom K. Choi, Geon Kook Lee, Seog‐Yun Park, Hyun‐ju Lim, Jung‐Ah Hwang, Jiyeon Lim, Ji‐Youn Han, Youngjoo Lee
      Cancer.2024;[Epub]     CrossRef
    • Surveillance for Distant Metastasis in Breast Cancer Patients Who Underwent Contemporary Management: A Report from the Korean Breast Cancer Society Survivor Research Group
      Jong-Ho Cheun, Sooyeon Chung, Jai Hong Han, Young-Won Lee, Ji-Jung Jung, Jung Whan Chun, Eun-Gyeong Lee, Jun Won Min, Zisun Kim, Jihyoun Lee, So-Youn Jung, Yoo Seok Kim, Jong Han Yu, Eun-Kyu Kim, Jong-Won Lee, Ki-Tae Hwang, Ku Sang Kim, Hyun Jo Youn, Hyeo
      Annals of Surgical Oncology.2024; 31(10): 6774.     CrossRef
    • Disparities in the diagnosis and treatment of colorectal cancer among patients with disabilities
      Ki Bae Kim, Dong Wook Shin, Kyoung Eun Yeob, So Young Kim, Joung-Ho Han, Seon Mee Park, Jong Heon Park, Jong Hyock Park
      World Journal of Gastrointestinal Oncology.2024; 16(7): 2925.     CrossRef
    • Optimization and Stabilization of Automated Synthesis Systems for Reduced 68Ga-PSMA-11 Synthesis Time
      Ji hoon KANG, Sang Min SHIN, Young Si PARK, Hea Ji KIM, Hwa Youn JANG
      Korean Journal of Clinical Laboratory Science.2024; 56(2): 147.     CrossRef
    • Clinical impact of pancreatic invasion in T1‐stage distal bile duct cancer and prognostic factors associated with long‐term survival: A multicenter study
      Ye Won Jeon, Chang Moo Kang, Yoo‐Seok Yoon, Wooil Kwon, Sung‐Sik Han, Yejong Park, Bong Jun Kwak, Woohyung Lee, Ki Byung Song, Jae Hoon Lee, Song Cheol Kim, Sang Hyun Shin, Dae Wook Hwang
      Journal of Hepato-Biliary-Pancreatic Sciences.2024; 31(9): 658.     CrossRef
    • Comparison of the treatment outcomes of different neoadjuvant chemoradiotherapy regimens for resectable locally advanced esophageal cancer
      Hyunki Park, Kyungmi Yang, Jae Myoung Noh, Young Mog Shim, Hong Kwan Kim, Yong Soo Choi, Jong Ho Cho, Jong-Mu Sun, Hyun Ae Jung, Sehhoon Park, Hana Park, Dongryul Oh
      Journal of Gastrointestinal Surgery.2024; 28(11): 1745.     CrossRef
    • Korean National Burden of Disease: The Importance of Diabetes Management
      Chung-Nyun Kim, Yoon-Sun Jung, Young-Eun Kim, Minsu Ock, Seok-Jun Yoon
      Diabetes & Metabolism Journal.2024; 48(4): 518.     CrossRef
    • Trends in multiple myeloma incidence, prevalence, mortality, and survival rate in South Korea: a nationwide population-based study
      Boyoung Park, Junghyun Yoon, YooSun Lee, YoungJu Park, Hyeon-Seok Eom
      Annals of Hematology.2024; 103(10): 4111.     CrossRef
    • Efficacy and safety of laser ablation and microwave ablation to treat papillary thyroid microcarcinoma: A retrospective study
      Yuqing Huang, Xinyu Zhao, Yu Yang, Lanyan Qiu, Junfeng Zhao, Linxue Qian, Xianquan Shi
      American Journal of Otolaryngology.2024; 45(6): 104496.     CrossRef
    • Insurance Types and All-Cause Mortality in Korean Cancer Patients: A Nationwide Population-Based Cohort Study
      Jinyoung Shin, Yoon-Jong Bae, Hee-Taik Kang
      Journal of Personalized Medicine.2024; 14(8): 861.     CrossRef
    • Disparities in Overall Survival Rates for Cancers across Income Levels in the Republic of Korea
      Su-Min Jeong, Kyu-Won Jung, Juwon Park, Hyeon Ji Lee, Dong Wook Shin, Mina Suh
      Cancers.2024; 16(16): 2923.     CrossRef
    • Interactions between vitamin B2, the MTRR rs1801394 and MTR rs1805087 genetic polymorphisms, and colorectal cancer risk in a Korean population
      Madhawa Gunathilake, Minji Kim, Jeonghee Lee, Jae Hwan Oh, Hee Jin Chang, Dae Kyung Sohn, Aesun Shin, Jeongseon Kim
      Epidemiology and Health.2024; 46: e2024037.     CrossRef
    • Clinical outcomes and safety of external beam radiotherapy with extensive intrahepatic targets for advanced hepatocellular carcinoma: A single institutional clinical experience
      Sunmin Park, Chai Hong Rim, Won Sup Yoon
      Saudi Journal of Gastroenterology.2024; 30(6): 399.     CrossRef
    • Is Chronic Ice Water Ingestion a Risk Factor for Gastric Cancer Development? An Evidence-Based Hypothesis Focusing on East Asian Populations
      Farzad Taghizadeh-Hesary
      Oncology and Therapy.2024; 12(4): 629.     CrossRef
    • Real-world safety and effectiveness of lenvatinib in unresectable hepatocellular carcinoma in Korea: post-marketing study
      Wonseok Kang, Yoon Jun Kim, Seung Up Kim, Yeon Seok Seo, Jin-Wook Kim, Ji Hoon Kim, Soo Young Park, Yang-Hyun Baek, Kang Mo Kim, Hae Lim Lee, Ki Tae Yoon, Hyeyeong Kim, Jae Youn Cheong, Jae Seok Hwang, Ju Hyun Kim, Kwang Min Kim, Pil Soo Sung, Jieun Kim,
      Future Oncology.2024; 20(37): 2949.     CrossRef
    • Thyroid cancer-specific mortality during 2005–2018 in Korea, aftermath of the overdiagnosis issue: a nationwide population-based cohort study
      Kyeong Jin Kim, Jimi Choi, Sue K. Park, Young Joo Park, Sin Gon Kim
      International Journal of Surgery.2024; 110(9): 5489.     CrossRef
    • Post-Treatment Experiences of Reproductive Concerns Among Young Breast Cancer Survivors: A Descriptive Phenomenological Study
      Wenjing Xu, Xiangyu Liu, Cuicui Zhang, Lili Zhu, Yuxiu Zhao, Changju Liao
      Asian Nursing Research.2024; 18(4): 331.     CrossRef
    • Regional Impact of the COVID-19 Pandemic on Cancer Screening
      Jongho Park, Yeaeun Kim, Jae-Hyun Park
      Asia Pacific Journal of Public Health.2024; 36(8): 760.     CrossRef
    • Incidence and pattern of second primary cancer in patients diagnosed with primary cancer
      Jong Sung, Ae Ahn, Ho Park, Kyu Jang, Woo Moon, Ju-Hyung Lee, Kyoung Kim, Myoung Chung
      Oncology Letters.2024;[Epub]     CrossRef
    • The effects of sarcopenic obesity on immediate postoperative outcomes after pancreatoduodenectomy: a retrospective cohort study
      Jae Hwan Jeong, Ji Su Kim, Seung-seob Kim, Seung Soo Hong, Ho Kyoung Hwang, Chang Moo Kang, Hyoung-Il Kim, Kyung Sik Kim, Sung Hyun Kim
      Annals of Surgical Treatment and Research.2024; 107(4): 203.     CrossRef
    • Prognostic Significance of Bulky Nodal Disease in Anal Cancer Management: A Multi-institutional Study
      Seok-Joo Chun, Eunji Kim, Won Il Jang, Mi-Sook Kim, Hyun-Cheol Kang, Byoung Hyuck Kim, Eui Kyu Chie
      Cancer Research and Treatment.2024; 56(4): 1197.     CrossRef
    • Lesson from COVID-19 outbreak; importance of standard precautions to febrile neutropenia prevention in patients with breast cancer who received adjuvant chemotherapy: a retrospective observational study
      Ji Eun Park, Jieun Yang, Sanghoon Han, Jeong Rae Yoo, Misun Kim, Donghyoun Lee, Jaemin Jo
      Annals of Surgical Treatment and Research.2024; 107(4): 195.     CrossRef
    • Development and Feasibility Evaluation of Smart Cancer Care 2.0 Based on Patient-Reported Outcomes for Post-Discharge Management of Patients with Cancer
      Jin Ah Kwon, Songsoo Yang, Su-Jin Koh, Young Ju Noh, Dong Yoon Kang, Sol Bin Yang, Eun Ji Kwon, Jeong-Wook Seo, Jin sung Kim, Minsu Ock
      Cancer Research and Treatment.2024; 56(4): 1040.     CrossRef
    • Re-evaluation of the role of endoscopic submucosal dissection in the treatment of early gastric cancer based on additional gastrectomy results
      Dong Won Im, Jae Hun Chung, Dae-Gon Ryu, Cheol Woong Choi, Su Jin Kim, Sun-Hwi Hwang, Si-Hak Lee
      Medicine.2024; 103(41): e40111.     CrossRef
    • Transforming public health and economic outcomes by reducing risky behaviors: the potential for South Korea
      Joan E. Madia, Ji Yoon Baek, Aesun Shin
      Discover Social Science and Health.2024;[Epub]     CrossRef
    • Prognostic value of the systemic immune-inflammation index in lung cancer patients receiving immune checkpoint inhibitors: A meta-analysis
      Yanhui Yang, Ji Li, Yi Wang, Lei Luo, Yi Yao, Xiaoyang Xie, Gayle E. Woloschak
      PLOS ONE.2024; 19(11): e0312605.     CrossRef
    • Cohort Profile: The Registry-based Epidemiological Study of Cancer in Fire Unit and Emergency Officers (RESCUE) cohort
      Wonjeong Jeong, Yoon A Kim, Soo Yeon Song, Dong-Hee Koh, Hyoung-Ryoul Kim, Jae-Lim Cho, Changsoo Kim, Jae Kwan Jun
      International Journal of Epidemiology.2024;[Epub]     CrossRef
    • The discrepancy of somatic BRCA1/2 pathogenic variants from two different platforms in epithelial ovarian, fallopian tube, and peritoneal cancer
      Ji Hyun Kim, Jun-Young Shin, Seog-Yun Park, Sang-Soo Seo, Sokbom Kang, Chong Woo Yoo, Sang-Yoon Park, Myong Cheol Lim
      Scientific Reports.2024;[Epub]     CrossRef
    • Application of a Novel Multimodal-Based Deep Learning Model for the Prediction of Papillary Thyroid Carcinoma Recurrence
      Dong-Hwa Lee, Jee-Woo Choi, Geun-Hyeong Kim, Seung Park, Hyun Jeong Jeon
      International Journal of General Medicine.2024; Volume 17: 6585.     CrossRef
    • Mismatch repair, p53, and L1 cell adhesion molecule status influence the response to chemotherapy in advanced and recurrent endometrial cancer
      Jung Chul Kim, Byungsoo Ahn, Yong Jae Lee, Eun Ji Nam, Sang Wun Kim, Sunghoon Kim, Young Tae Kim, Eunhyang Park, Jung-Yun Lee
      BMC Cancer.2024;[Epub]     CrossRef
    • Thyroid cancer survival and prognostic factors in Yantai, China (2012–2022): a population-based study
      Haiyun Liu, Shuxia Zhang, Xiaohui Liu, Qianqian Wang, Hongjie Zhang, Weihong Cui
      BMC Cancer.2024;[Epub]     CrossRef
    • Dietary mercury intake, the IL23R rs10889677 polymorphism, and the risk of gastric cancer in a Korean population: a hospital-based case-control study
      Ji Hyun Kim, Madhawa Gunathilake, Jeonghee Lee, Il Ju Choi, Young-Il Kim, Jeongseon Kim
      Epidemiology and Health.2024; 46: e2024051.     CrossRef
    • Validation of self-reported morbidities in the Korean Atomic Bomb Survivor Cohort
      Ansun Jeong, Somin Jeon, Seong-geun Moon, Mi Kyung Kim, Inah Kim, Yu-Mi Kim, Boyoung Park
      Epidemiology and Health.2024; 46: e2024058.     CrossRef
    • Efficacy of a Mobile App for Assisting in the Self-management of Patients with Breast Cancer on Self-efficacy: A Non-randomized Intervention Trial (Preprint)
      Sun Mi Kim, Da Seul Kim, Yoonsung Jang, Min Kyoon Kim, Eun-Seung Yu, Doug Hyun Han, Hee Jun Kim
      JMIR mHealth and uHealth.2024;[Epub]     CrossRef
    • Current treatment patterns within 1 year after prostate cancer diagnosis in Korean patients over 75 years old: a retrospective multicenter study
      Dong Jin Park, Ho Won Kang, Se Yun Kwon, Young Jin Seo, Kyung Seop Lee, Byung Hoon Kim, Teak Jun Shin, Won Tae Kim, Yong-June Kim, Seok Joong Yun, Sang-Cheol Lee, Jae-Wook Chung, Seock Hwan Choi, Jun Nyung Lee, Hyun Tae Kim, Tae-Hwan Kim, Eun Sang Yoo, Ta
      Prostate International.2023; 11(1): 34.     CrossRef
    • Prognostic roles of leptin‐signaling proteins, PD‐L1, and tumor‐infiltrating lymphocytes in surgically‐resected biliary tract cancers
      Sun‐ju Byeon, Mee Soo Chang, Hwa Jin Cho, Jeong Hwan Park, Ki Hwan Kim, Jin Hyun Park, In Sil Choi, Won Kim, Dong‐Seok Han, Hye Seong Ahn, Seung Chul Heo
      Journal of Surgical Oncology.2023; 127(4): 587.     CrossRef
    • SLC17A9-PTHLH-EMT axis promotes proliferation and invasion of clear renal cell carcinoma
      Weiquan Li, Ning Xu, Xiangui Meng, Hongwei Yuan, Tiexi Yu, Qi Miao, Hongmei Yang, Bo Hai, Wen Xiao, Xiaoping Zhang
      iScience.2023; 26(1): 105764.     CrossRef
    • Effects of a Post-Traumatic Growth Program on Young Korean Breast Cancer Survivors
      Ka Ryeong Bae, Wi-Young So, Seyong Jang
      Healthcare.2023; 11(1): 140.     CrossRef
    • Cost-effectiveness of hyperthermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III-IV ovarian cancer from a randomized controlled phase III trial in Korea (KOV-HIPEC-01)
      Ji Hyun Kim, Sung-Youn Chun, Dong-eun Lee, Yo Han Woo, Suk-Joon Chang, Sang-Yoon Park, Yoon Jung Chang, Myong Cheol Lim
      Gynecologic Oncology.2023; 170: 19.     CrossRef
    • Does the presence of a micropapillary component predict worse prognosis in pathological stage IA lung adenocarcinoma?
      Yan Wang, Wenpeng Song, Xin Wang, Guowei Che
      Pathology - Research and Practice.2023; 242: 154314.     CrossRef
    • Investigation of the female infertility risk associated with anti-cancer therapy
      Atiye Lavafian, Parmida Sadat Pezeshki, Nima Rezaei
      Clinical and Translational Oncology.2023; 25(7): 1893.     CrossRef
    • Lung Imaging Reporting and Data System (Lung-RADS) in Radiology: Strengths, Weaknesses and Improvement
      Gong Yong Jin
      Journal of the Korean Society of Radiology.2023; 84(1): 34.     CrossRef
    • Deep learning approach to detection of colonoscopic information from unstructured reports
      Donghyeong Seong, Yoon Ho Choi, Soo-Yong Shin, Byoung-Kee Yi
      BMC Medical Informatics and Decision Making.2023;[Epub]     CrossRef
    • Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC)
      Jieun Lee
      Journal of Clinical Medicine.2023; 12(4): 1524.     CrossRef
    • Association between dietary habits and incident thyroid cancer: A prospective cohort study
      Linh Thi Dieu Nguyen, Madhawa Gunathilake, Jeonghee Lee, Jeongseon Kim
      Frontiers in Nutrition.2023;[Epub]     CrossRef
    • Regional lymph node recurrence after stereotactic body radiation therapy for lung cancer: Patterns of recurrence, treatment approaches, and clinical outcomes (KROG 21-09)
      Tae Hoon Lee, Hyunju Shin, Yong Chan Ahn, Min Kyu Kang, Changhoon Song, Woo Chul Kim, Sung Ho Moon, Jin Hee Kim, Jaeho Cho, Hae Jin Park, Heui Kwan Lee, Byoung Hyuck Kim, Hak Jae Kim
      Radiotherapy and Oncology.2023; 183: 109572.     CrossRef
    • Addition of metformin for non-small cell lung cancer patients receiving antineoplastic agents
      Yan Wang, Yuanyuan Hu, Ting Wang, Guowei Che, Lu Li
      Frontiers in Pharmacology.2023;[Epub]     CrossRef
    • Parental Factors Affecting Decision to Vaccinate Their Daughters against Human Papillomavirus
      Yoon Park, Moran Ki, Hyunju Lee, Jae-Kwan Lee, Jin-Kyoung Oh
      Cancer Prevention Research.2023; 16(3): 133.     CrossRef
    • Underuse of Gastric Cancer Screening Services among Koreans with Type 2 Diabetes
      Kumban Walter Chuck, Seri Hong, Yunhwan Lee
      Healthcare.2023; 11(7): 927.     CrossRef
    • Association of Dietary Fiber Intake With Gastrointestinal Tract Cancer Among Korean Adults
      Shinyoung Jun, Jeonghee Lee, Jeongseon Kim
      JAMA Network Open.2023; 6(3): e234680.     CrossRef
    • Prognostic value of deep learning–based fibrosis quantification on chest CT in idiopathic pulmonary fibrosis
      Ju Gang Nam, Yunhee Choi, Sang-Min Lee, Soon Ho Yoon, Jin Mo Goo, Hyungjin Kim
      European Radiology.2023; 33(5): 3144.     CrossRef
    • Effective Timing of Introducing an Inpatient Smoking Cessation Program to Cancer Patients
      Yu-Ri Choe, Ji-Won Choi, Ju-Ri Jeong, Hye-Mi Doh, Mi-Lee Kim, Min-Seol Nam, Hee-Ji Kho, Ha-Young Park, Hye-Ran Ahn, Sun-Seog Kweon, Yu-Il Kim, In-Jae Oh
      Yonsei Medical Journal.2023; 64(4): 251.     CrossRef
    • Stereotactic Body Radiation Therapy for Pulmonary Metastasis from Colorectal Adenocarcinoma: Biologically Effective Dose 150 Gy is Preferred for Tumour Control
      T.H. Lee, H.-C. Kang, E.K. Chie, H.J. Kim, H.-G. Wu, J.H. Lee, K.S. Kim
      Clinical Oncology.2023; 35(6): e384.     CrossRef
    • High-Resolution Tactile-Sensation Diagnostic Imaging System for Thyroid Cancer
      So-Hyun Cho, Su-Min Lee, Na-Young Lee, Byoung Chul Ko, Hojeong Kim, Dae-Jin Jang, Jong-Ha Lee
      Sensors.2023; 23(7): 3451.     CrossRef
    • Quality Assessment and Trend for Breast Cancer Treatment Practice across South Korea Based on Nationwide Analysis of Korean Health Insurance Data during 2013-2017
      Kyu Hye Choi, Soo-Yoon Sung, Sea-Won Lee, Ye Won Jeon, Sung Hwan Kim, Jong Hoon Lee
      Cancer Research and Treatment.2023; 55(2): 570.     CrossRef
    • Patterns and Longitudinal Changes in the Practice of Breast Cancer Radiotherapy in Korea: Korean Radiation Oncology Group 22-01
      Hae Jin Park, Kyubo Kim, Yong Bae Kim, Jee Suk Chang, Kyung Hwan Shin
      Journal of Breast Cancer.2023; 26(3): 254.     CrossRef
    • Sex-specific effects of fruit, vegetable, and red meat intake on the risk of gastric and esophageal cancer in a large cohort
      Su Youn Nam, Junwoo Jo, Seong Woo Jeon, Hyonho Chun
      Digestive and Liver Disease.2023; 55(10): 1403.     CrossRef
    • Novel thrombospondin-1 transcript exhibits distinctive expression and activity in thyroid tumorigenesis
      Yukyung Hong, Ilju Kim, Hyunjin Moon, Jaehak Lee, Pattawika Lertpatipanpong, Chang Hwan Ryu, Yuh-Seog Jung, Jungirl Seok, Yonghwan Kim, Junsun Ryu, Seung Joon Baek
      Oncogene.2023; 42(22): 1832.     CrossRef
    • Comparison of a Tobacco-Specific Carcinogen in Tobacco Cigarette, Electronic Cigarette, and Dual Users
      Jae-woo Lee, Sukil Kim
      Journal of Korean Medical Science.2023;[Epub]     CrossRef
    • Licochalcone A Exerts Anti-Cancer Activity by Inhibiting STAT3 in SKOV3 Human Ovarian Cancer Cells
      Jeonghyeon Seo, Da Eun Lee, Seong Mi Kim, Eunjung Kim, Jin-Kyung Kim
      Biomedicines.2023; 11(5): 1264.     CrossRef
    • Conization before radical hysterectomy in patients with early-stage cervical cancer: A Korean multicenter study (COBRA-R)
      Se Ik Kim, So Hyun Nam, Suhyun Hwangbo, Yeorae Kim, Hyun-Woong Cho, Dong Hoon Suh, Jae Yun Song, Jae-Weon Kim, Chel Hun Choi, Dae-Yeon Kim, Maria Lee
      Gynecologic Oncology.2023; 173: 88.     CrossRef
    • Association between changes in having of cancer patients in the family and depression: A longitudinal panel study
      Yun Seo Jang, Na-Young Yoon, Kyungduk Hurh, Eun-Cheol Park, Min Jin Ha
      Journal of Affective Disorders.2023; 333: 482.     CrossRef
    • Risk factors of recurrence in TNM stage I colorectal cancer
      Jin-Hee Paik, Chun-Geun Ryu, Dae-Yong Hwang
      Annals of Surgical Treatment and Research.2023; 104(5): 281.     CrossRef
    • Fertility-sparing hormonal treatment in patients with stage I endometrial cancer of grade 2 without myometrial invasion and grade 1–2 with superficial myometrial invasion: Gynecologic Oncology Research Investigators coLLaborAtion study (GORILLA-2001)
      A Jin Lee, Eun Jung Yang, Nam Kyeong Kim, Yeorae Kim, Dong Hoon Suh, Jeeyeon Kim, Joo-Hyuk Son, Tae-Wook Kong, Suk-Joon Chang, Dong Won Hwang, Soo Jin Park, Hee Seung Kim, Ji Geun Yoo, Sung Jong Lee, Yoo-Young Lee, Seung-Hyuk Shim
      Gynecologic Oncology.2023; 174: 106.     CrossRef
    • Gut microbiome associated with low anterior resection syndrome after rectal cancer surgery
      Min Jung Kim, Soyoung Park, Ji Won Park, Jinsun Choi, Hyo Jun Kim, Han-Ki Lim, Seung-Bum Ryoo, Kyu Joo Park, Yosep Ji, Seung-Yong Jeong
      Scientific Reports.2023;[Epub]     CrossRef
    • Increased risk of pancreatic, thyroid, prostate and breast cancers in men with a family history of breast cancer: A population‐based study
      Huiyeon Song, Yoon Suk Jung, Thi Xuan Mai Tran, Chang Mo Moon, Boyoung Park
      International Journal of Cancer.2023; 153(5): 950.     CrossRef
    • National Cancer Control Plan of the Korea: Current Status and the Fourth Plan (2021-2025)
      Kyu-Tae Han, Jae Kwan Jun, Jeong-Soo Im
      Journal of Preventive Medicine and Public Health.2023; 56(3): 205.     CrossRef
    • Breast Cancer Statistics in Korea, 2019
      Jung Eun Choi, Zisun Kim, Chan Sub Park, Eun Hwa Park, Sae Byul Lee, Se Kyung Lee, Young Jin Choi, Jaihong Han, Kyu-Won Jung, Hee Jeong Kim, Hyun-Ah Kim
      Journal of Breast Cancer.2023; 26(3): 207.     CrossRef
    • Early-onset stroke among people with disabilities: a national database study in South Korea from 2008 to 2017
      Hee Soo Yang, So Young Kim, Min Jae Jo, Yeon Yong Kim, Jong Hyock Park
      The Lancet Regional Health - Western Pacific.2023; 38: 100819.     CrossRef
    • Importance of Early Surveillance Endoscopy in Patients at a High Risk of Gastric Cancer
      Sang Hoon Kim
      The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2023; 23(2): 151.     CrossRef
    • Impact of pre‐ and post‐diagnosis physical activity on the mortality of patients with cancer: Results from the Health Examinees‐G study in Korea
      Jaesung Choi, Joo‐Yong Park, Ji‐Eun Kim, Miyoung Lee, Kyuwan Lee, Jong‐Koo Lee, Daehee Kang, Aesun Shin, Ji‐Yeob Choi
      Cancer Medicine.2023; 12(15): 16591.     CrossRef
    • Significance of The Regular Publication of Statistics on National Health Indicators in Academic Journals and The Prospects of Korea National Antimicrobial Use Analysis System (KONAS)
      Bongyoung Kim, Yong Chan Kim, Hyung-Sook Kim, Se Yoon Park, Jun Yong Choi
      Infection & Chemotherapy.2023; 55(2): 306.     CrossRef
    • Predictive role of pretreatment skeletal muscle mass index for long-term survival of bladder cancer patients: A meta-analysis
      Qian Yuan, Jianrong Hu, Feng Yuan, Jingjing An, Andrea D’Aviero
      PLOS ONE.2023; 18(6): e0288077.     CrossRef
    • Is Fragmented Cancer Care Associated With Medical Expenditure? Nationwide Evidence From Patients With Lung Cancer Using National Insurance Claim Data
      Kyu-Tae Han, Sun Jung Kim
      International Journal of Public Health.2023;[Epub]     CrossRef
    • Genomic and evolutionary characteristics of metastatic gastric cancer by routes
      Jae Eun Lee, Ki Tae Kim, Su-Jin Shin, Jae-Ho Cheong, Yoon Young Choi
      British Journal of Cancer.2023; 129(4): 672.     CrossRef
    • The incidence and risk factors of occult malignancy in patients receiving vaginal hysterectomy for pelvic organ prolapse
      Soo Min Ryu, Jeong Soo Cho, Mi Kyung Kong, Sang Wook Bai
      International Urogynecology Journal.2023; 34(11): 2719.     CrossRef
    • Overview of the National Cancer Screening Program for Colorectal Cancer in Korea over 14 Years (2004-2017)
      Bomi Park, Eun Young Her, Kyeongmin Lee, Fatima Nari, Jae Kwan Jun, Kui Son Choi, Mina Suh
      Cancer Research and Treatment.2023; 55(3): 910.     CrossRef
    • Urologic malignancies that cause hematuria
      Sung Jin Kim, Myungchan Park, Sangjun Yoo
      Journal of the Korean Medical Association.2023; 66(6): 363.     CrossRef
    • Right Then, Wrong Now: Early-Onset Colorectal Cancer in Korea
      Aesun Shin, Kyu-Won Jung, Seung-Yong Jeong
      Cancer Research and Treatment.2023; 55(3): 1058.     CrossRef
    • Single-center study on clinicopathological and typical molecular pathologic features of metastatic brain tumor
      Su Hwa Kim, Young Suk Lee, Sung Hak Lee, Yeoun Eun Sung, Ahwon Lee, Jun Kang, Jae-Sung Park, Sin Soo Jeun, Youn Soo Lee
      Journal of Pathology and Translational Medicine.2023; 57(4): 217.     CrossRef
    • Crataegus pinnatifida Bunge root extract induces apoptosis of murine lung carcinoma cells in vitro
      Minjeong Kwon, Jongbeom Chae, Ju-Ock Nam
      Journal of Applied Biological Chemistry.2023;[Epub]     CrossRef
    • Changes in spatial clusters of cancer incidence and mortality over 15 years in South Korea: Implication to cancer control
      Cham Thi Nguyen, Insang Song, Inkyung Jung, Yoon‐Jung Choi, Sun‐Young Kim
      Cancer Medicine.2023; 12(16): 17418.     CrossRef
    • Factors Associated with Dietary Habit Changes in Korean Stomach Cancer Survivors after Cancer Treatment
      Junhee Park, Jiyoung Kim, Dong Wook Shin, Jinyoung Shin, Belong Cho, Yun-Mi Song
      Nutrients.2023; 15(14): 3268.     CrossRef
    • Individual and joint effect of socioeconomic status and lifestyle factors on cancer in Korea
      Chi Lan Tran, Kui Son Choi, Sun‐Young Kim, Jin‐Kyoung Oh
      Cancer Medicine.2023; 12(16): 17389.     CrossRef
    • Racial differences in long-term social, physical, and psychological health among adolescent and young adult cancer survivors
      Sooyeon Kim, Juhee Cho, Dong Wook Shin, Su-Min Jeong, Danbee Kang
      BMC Medicine.2023;[Epub]     CrossRef
    • Changes in metabolic syndrome and the risk of breast and endometrial cancer according to menopause in Korean women
      Thi Xuan Mai Tran, Soyeoun Kim, Boyoung Park
      Epidemiology and Health.2023; 45: e2023049.     CrossRef
    • Operational Definitions of Colorectal Cancer in the Korean National Health Insurance Database
      Hyeree Park, Yu Rim Kim, Yerin Pyun, Hyundeok Joo, Aesun Shin
      Journal of Preventive Medicine and Public Health.2023; 56(4): 312.     CrossRef
    • Thromboembolic events in patients who received adjuvant chemotherapy for gastric cancer: a single-center retrospective study
      Tae-Hwan Kim, Jin-Hyuk Choi, Sang Min Jeon, Yong Won Choi, Minsuk Kwon, Hyun Woo Lee, Seok Yun Kang, Mi Sun Ahn, Sang-Yong Son, Hoon Hur, Sang-Uk Han, Seung-Soo Sheen
      Gastric Cancer.2023; 26(6): 1012.     CrossRef
    • Comprehensive Analysis of Iron Deficiency Anemia and Its Related Disorders in Premenopausal Women Based on a Propensity Score Matching Case Control Study Using National Health Insurance Service Database in Korea
      Hyun Jung Lee, Haeyong Pak, Jae Joon Han, Myung Hee Chang
      Journal of Korean Medical Science.2023;[Epub]     CrossRef
    • Edible mushroom intake and risk of all-cause and cause-specific mortality: results from the Korean Genome and Epidemiology Study (KoGES) Cohort
      Hyein Jung, JiAe Shin, Kyungjoon Lim, Sangah Shin
      Food & Function.2023; 14(19): 8829.     CrossRef
    • Risk of Subsequent Primary Cancer in Thyroid Cancer Survivors: A Nationwide Population-Based Study
      Min-Su Kim, Sang Jun Lee, Myeong Hoon Lee, Jay Hyug Choi, Hyun Wook Han, Young Shin Song
      Diagnostics.2023; 13(18): 2903.     CrossRef
    • The effect of the introduction of the national lung cancer screening program on short-term mortality in Korea
      Woorim Kim, Sang Chul Lee, Woo-Ri Lee, Sungyoun Chun
      Lung Cancer.2023; 186: 107412.     CrossRef
    • Cluster of lifestyle risk factors for stomach cancer and screening behaviors among Korean adults
      Thao Thi Kim Trinh, Kyeongmin Lee, Jin-Kyoung Oh, Mina Suh, Jae Kwan Jun, Kui Son Choi
      Scientific Reports.2023;[Epub]     CrossRef
    • The role of LOXL2 induced by glucose metabolism-activated NF-κB in maintaining drug resistance through EMT and cancer stemness in gemcitabine-resistant PDAC
      Yun Sun Lee, Hyung Sun Kim, Hyo Jung Kim, Hyeon Woong Kang, Da Eun Lee, Myeong Jin Kim, Woosol Chris Hong, Ju Hyun Kim, Minsoo Kim, Jae-Ho Cheong, Joon Seong Park
      Journal of Molecular Medicine.2023; 101(11): 1449.     CrossRef
    • Analysis of the Spread of Misinformation about Lung Cancer on YouTube: Based on Source of Information
      Hangsoo Park, EunKyo Kang, Yeol Kim, HyoRim Ju
      Korean Journal of Family Practice.2023; 13(3): 152.     CrossRef
    • Zinc intake, SLC30A8 rs3802177 polymorphism, and colorectal cancer risk in a Korean population: a case–control study
      Linh Thi Dieu Nguyen, Madhawa Gunathilake, Jeonghee Lee, Jae Hwan Oh, Hee Jin Chang, Dae Kyung Sohn, Aesun Shin, Jeongseon Kim
      Journal of Cancer Research and Clinical Oncology.2023; 149(18): 16429.     CrossRef
    • Nivolumab as maintenance therapy following platinum‐based chemotherapy in EGFR‐mutant lung cancer patients after tyrosine kinase inhibitor failure: A single‐arm, open‐label, phase 2 trial
      Jiwon Kim, Chang‐Min Choi, Wonjun Ji, Jae Cheol Lee
      Thoracic Cancer.2023; 14(31): 3080.     CrossRef
    • Exploring the past, present, and future of postoperative radiotherapy for N2 stage non-small cell lung cancer
      Byoung Hyuck Kim, Jae Sik Kim, Hak Jae Kim
      Radiation Oncology Journal.2023; 41(3): 144.     CrossRef
    • Clinical implications of RAB13 expression in pan-cancer based on multi-databases integrative analysis
      Xu-dong Zhang, Zhong-yuan Liu, Kai Luo, Xiang-kun Wang, Mao-sen Wang, Shuai Huang, Ren-feng Li
      Scientific Reports.2023;[Epub]     CrossRef
    • Post-percutaneous core needle biopsy sputum cytology: diagnostic value and factors for positive prediction in diagnosing malignancy
      Sang Kyu Lee, Hee Kang, Min Jung Jung, Sekyoung Park, Ki Nam Lee
      Kosin Medical Journal.2023; 38(3): 201.     CrossRef
    • Rigid bronchoscopic intervention for malignant central airway obstruction: A narrative review
      Byeong-Ho Jeong, Hojoong Kim
      Precision and Future Medicine.2023; 7(3): 95.     CrossRef
    • Optimal Cutoff Values of the Contact Angle of Tumor on Sonography System for Predicting Extrathyroidal Extension of Papillary Thyroid Carcinoma by Tumor Location
      Ik Beom Shin, Do Hoon Koo, Dong Sik Bae
      Clinical Medicine Insights: Oncology.2023;[Epub]     CrossRef
    • Large colonic lipoma with a laterally spreading tumor treated by endoscopic submucosal dissection: A case report
      Jun Yong Bae, Hun Kyu Kim, Yee Jin Kim, Se Woong Kim, Youngeun Lee, Chang Beom Ryu, Moon Sung Lee
      World Journal of Clinical Cases.2023; 11(26): 6194.     CrossRef
    • Increased Screening Rates for Thyroid Cancer Among Residents Living Near Nuclear Power Plants
      Ga Bin Lee, Soojin Park, Won Il Jang, Sunhoo Park, Jae Kwan Jun, Songwon Seo
      Journal of Korean Medical Science.2023;[Epub]     CrossRef
    • Cancer risks in patients with psoriasis administered biologics therapy: a nationwide population-based study
      Joon Min Jung, Ye-Jee Kim, Sung Eun Chang, Mi Woo Lee, Chong Hyun Won, Woo Jin Lee
      Journal of Cancer Research and Clinical Oncology.2023; 149(19): 17093.     CrossRef
    • Final Report on Real-World Effectiveness of Sequential Afatinib and Osimertinib in EGFR-Positive Advanced Non–Small Cell Lung Cancer: Updated Analysis of the RESET Study
      Taeyun Kim, Tae Won Jang, Chang Min Choi, Mi-Hyun Kim, Sung Yong Lee, Yoon Soo Chang, Kye Young Lee, Seung Joon Kim, Sei Hoon Yang, Jeong Seon Ryu, Jeong Eun Lee, Shin Yup Lee, Chan Kwon Park, Sang Hoon Lee, Seung Hun Jang, Seong Hoon Yoon, Hyung-Joo Oh
      Cancer Research and Treatment.2023; 55(4): 1152.     CrossRef
    • The Multidomain Metaverse Cancer Care Digital Platform: Development and Usability Study
      Sunghak Kim, Timothy Jung, Dae Kyung Sohn, Yoon Chae, Young Ae Kim, Seung Hyun Kang, Yujin Park, Yoon Jung Chang
      JMIR Serious Games.2023; 11: e46242.     CrossRef
    • Knowledge mapping of immunotherapy for thyroid cancer from 1980 to 2022: A review
      Ran Ding, Hongguan Jiao, Yuanlin Piao, Weiyi Tian
      Medicine.2023; 102(39): e35506.     CrossRef
    • Alzheimer’s Disease and Different Types of Cancer Likelihood: Unveiling Disparities and Potential Protective Effects in a Korean Cohort Study
      Ho Suk Kang, Ji Hee Kim, Hyun Lim, Joo-Hee Kim, Hye-Mi Noh, Hyo Geun Choi, Kyueng-Whan Min, Nan Young Kim, Mi Jung Kwon
      Cancers.2023; 15(18): 4615.     CrossRef
    • Association between gut microbial change and acute gastrointestinal toxicity in patients with prostate cancer receiving definitive radiation therapy
      Bum‐Sup Jang, Moon Gyu Chung, Dong Soo Lee
      Cancer Medicine.2023; 12(22): 20727.     CrossRef
    • Health Behaviors of Cancer Survivors According to the Employment Status and Occupation: A Cross-Sectional Study
      Ka Ryeong Bae, Wi-Young So, Su Jung Lee
      Healthcare.2023; 11(22): 2974.     CrossRef
    • Predictive factors of lymph node metastasis in papillary thyroid cancer
      Woo Jin Song, In Chan Um, Sa Rang Kwon, Jin Ho Lee, Hye Won Lim, Yong Uk Jeong, Seung Min Chung, Jun Sung Moon, Ji Sung Yoon, Kyu Chang Won, Hyoung Woo Lee, Adeel Ahmad Khan
      PLOS ONE.2023; 18(11): e0294594.     CrossRef
    • Exocrine pancreatic cancer as a second primary malignancy: A population-based study
      Mee Joo Kang, Jiwon Lim, Sung-Sik Han, Hyeong Min Park, Sung Chun Cho, Sang-Jae Park, Sun-Whe Kim, Young-Joo Won
      Annals of Hepato-Biliary-Pancreatic Surgery.2023; 27(4): 415.     CrossRef
    • Disparities in Cancer Incidence across Income Levels in South Korea
      Su-Min Jeong, Kyu-Won Jung, Juwon Park, Nayeon Kim, Dong Wook Shin, Mina Suh
      Cancers.2023; 15(24): 5898.     CrossRef
    • Frailty in Geriatric Patients with Head and Neck Cancer and its Implication in Survivorship
      Minsu Kwon
      Korean Society for Head and Neck Oncology.2023; 39(2): 1.     CrossRef
    • Application of Artificial Intelligence in Breast Imaging: Current Landscape and Prospects
      Hee Jeong Kim, Hak Hee Kim
      Korean Journal of Family Practice.2023; 13(4): 196.     CrossRef
    • Disparities of health expenditure associated with the experience of admission in long-term care hospital among patients with colorectal cancer in South Korea: A generalized estimating equation
      Woo-Ri Lee, Noorhee Son, Ki-Bong Yoo, Kyu-Tae Han, Sina Azadnajafabad
      PLOS ONE.2023; 18(12): e0296170.     CrossRef
    • Interaction between vitamin E intake and a COMT gene variant on colorectal cancer risk among Korean adults: a case-control study
      Shinyoung Jun, Madhawa Gunathilake, Jeonghee Lee, Jae Hwan Oh, Hee Jin Chang, Dae Kyung Sohn, Aesun Shin, Jeongseon Kim
      Epidemiology and Health.2023; 45: e2023100.     CrossRef
    • Parental intention to vaccinate daughters with the human papillomavirus vaccine in Korea: a nationwide cross-sectional survey
      Yejin Ha, Kyeongmin Lee, Bomi Park, Mina Suh, Jae Kwan Jun, Kui Son Choi
      Epidemiology and Health.2023; 45: e2023076.     CrossRef
    • Adherence to the World Cancer Research Fund/American Institute for Cancer Research and Korean Cancer Prevention Guidelines and cancer risk: a prospective cohort study from the Health Examinees-Gem study
      Jeeyoo Lee, Aesun Shin, Woo-Kyoung Shin, Ji-Yeob Choi, Daehee Kang, Jong-Koo Lee
      Epidemiology and Health.2023; 45: e2023070.     CrossRef
    • Genetically determined alcohol consumption and cancer risk in Korea
      Keum Ji Jung, Ji Woo Baek, Sang Yop Shin, Sun Ha Jee
      Epidemiology and Health.2023; 45: e2023077.     CrossRef
    • Dietary intake and cancer incidence in Korean adults: a systematic review and meta-analysis of observational studies
      Ji Hyun Kim, Shinyoung Jun, Jeongseon Kim
      Epidemiology and Health.2023; 45: e2023102.     CrossRef
    • Comparison of Long-Term Survival Between cT1N0 Stage Esophageal Cancer Patients Receiving Endoscopic Dissection and Esophagectomy: A Meta-Analysis
      Wei Lu, Peng Li, Wu Wen, Yi Jian
      Frontiers in Surgery.2022;[Epub]     CrossRef
    • Feasibility of Indocyanine Green Fluorescence Lymph Node Mapping for Radical Colectomy of Mid-Transverse and Left-Sided Colon Cancer
      Soo Yeun Park, Jun Seok Park, Hye Jin Kim, Gyu-Seog Choi
      Annals of Robotic and Innovative Surgery.2022; 3(1): 1.     CrossRef
    • A New Chemotherapy Paradigm in Advanced Esophageal Cancer
      Jang Ho Cho
      Journal of Digestive Cancer Research.2022; 10(1): 43.     CrossRef
    • Current Evidence for a Paradigm Shift in Gastric Cancer Prevention From Endoscopic Screening toHelicobacter pyloriEradication in Korea
      Young-Il Kim, Il Ju Choi
      Journal of Gastric Cancer.2022; 22(3): 169.     CrossRef
    • Particulate Matter Exposure after a Cancer Diagnosis and All-Cause Mortality in a Regional Cancer Registry-Based Cohort in South Korea
      Sang-Yong Eom, Yong-Dae Kim, Heon Kim
      International Journal of Environmental Research and Public Health.2022; 19(16): 9875.     CrossRef
    • Open versus minimally invasive radical hysterectomy for early cervical cancer: A two-center retrospective cohort study with pathologic review of usual-type adenocarcinoma and adenosquamous carcinoma
      Yeorae Kim, Se Ik Kim, Hyojin Kim, Maria Lee, Hee Seung Kim, Kidong Kim, Hyun Hoon Chung, Jae Hong No, Yong Beom Kim, Jae-Weon Kim, Noh Hyun Park, Yong-Sang Song, Cheol Lee, Dong Hoon Suh
      Gynecologic Oncology.2022; 167(1): 28.     CrossRef
    • Healthcare vulnerability disparities in pancreatic cancer treatment and mortality using the Korean National Sample Cohort: a retrospective cohort study
      Sung Hoon Jeong, Hyeon Ji Lee, Choa Yun, Il Yun, Yun Hwa Jung, Soo Young Kim, Hee Seung Lee, Sung-In Jang
      BMC Cancer.2022;[Epub]     CrossRef
    • Incidence, mortality, and survival of liver cancer using Korea central cancer registry database: 1999-2019
      Sung Yeon Hong, Mee Joo Kang, Taegyu Kim, Kyu-Won Jung, Bong-Wan Kim
      Annals of Hepato-Biliary-Pancreatic Surgery.2022; 26(3): 211.     CrossRef
    • Incidence, mortality and survival of gallbladder, extrahepatic bile duct, and pancreatic cancer using Korea central cancer registry database: 1999-2019
      Mee Joo Kang, E Hwa Yun, Kyu-Won Jung, Sang-Jae Park
      Annals of Hepato-Biliary-Pancreatic Surgery.2022; 26(3): 220.     CrossRef
    • The Effects of Lifestyle and Self-rated Health on Mental Health of Breast Cancer Survivors: Using Propensity Score Matching Approach
      Hyeng Sook Yoon, Eunjung Ryu
      Korean Journal of Adult Nursing.2022; 34(4): 369.     CrossRef
    • Factors Associated with Cyto-Histological Misinterpretation of Cervical Smear according to Menopausal Status
      Min Seong Choi, Young Jin Lee, Eun Hyun Lee, Yong Il Ji, Min Jeong Park
      Journal of Menopausal Medicine.2022; 28(2): 78.     CrossRef
    • 2021 Consensus Statements on the Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma From the Korean Renal Cancer Study Group (KRoCS)
      Chan Ho Lee, Minyong Kang, Cheol Kwak, Sung Han Kim, Jung Kwon Kim, Jae Young Park, Seong Il Seo, Ill Young Seo, Jungyo Suh, Wan Song, Cheryn Song, Hyeong Dong Yuk, Sangchul Lee, Hyung Ho Lee, Jinsoo Chung, Chang Wook Jeong, Jung Ki Jo, Chang Il Choi, Seo
      The Korean Journal of Urological Oncology.2022; 20(3): 151.     CrossRef
    • Cancer Rehabilitation Fact Sheet in Korea
      Jin A Yoon, Bo Young Hong
      Annals of Rehabilitation Medicine.2022; 46(4): 155.     CrossRef
    • Stereotactic body radiation therapy for elderly patients with small hepatocellular carcinoma: a retrospective observational study
      Jeong Yun Jang, Jinhong Jung, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jin-hong Park, Sang Min Yoon
      Journal of Liver Cancer.2022; 22(2): 136.     CrossRef
    • The Feasibility of Stereotactic Body Proton Beam Therapy for Pancreatic Cancer
      Hyunju Shin, Jeong Il Yu, Hee Chul Park, Gyu Sang Yoo, Sungkoo Cho, Joon Oh Park, Kyu Taek Lee, Kwang Hyuck Lee, Jong Kyun Lee, Joo Kyung Park, Jin Seok Heo, In Woong Han, Sang Hyun Shin
      Cancers.2022; 14(19): 4556.     CrossRef
    • Association between Obesity Indexes and Thyroid Cancer Risk in Korean Women: Nested Case–Control Study
      Yoonyoung Jang, Taehwa Kim, Brian H. S. Kim, Boyoung Park
      Cancers.2022; 14(19): 4712.     CrossRef
    • Impact of Cardiovascular Diseases on Mortality in Gastric Cancer Patients with Preexisting Chronic Disease
      Kyu-Tae Han, Dong Wook Kim, Woorim Kim
      Yonsei Medical Journal.2022; 63(11): 1043.     CrossRef
    • Direction of diagnosis and treatment improvement in colorectal cancer
      In Ja Park
      Journal of the Korean Medical Association.2022; 65(9): 540.     CrossRef
    • Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: A meta-analysis
      Se Ik Kim, Ji Hyun Kim, Sanghee Lee, Hyunsoon Cho, Willemien J. van Driel, Gabe S. Sonke, Robert E. Bristow, Sang-Yoon Park, Christina Fotopoulou, Myong Cheol Lim
      Gynecologic Oncology.2022; 167(3): 547.     CrossRef
    • Exposure to multiple trace elements and thyroid cancer risk in Chinese adults: A case-control study
      Jia-liu He, Hua-bing Wu, Wen-lei Hu, Jian-jun Liu, Qian Zhang, Wei Xiao, Ming-jun Hu, Ming Wu, Fen Huang
      International Journal of Hygiene and Environmental Health.2022; 246: 114049.     CrossRef
    • Respiratory Tract Cancer Incidences across Industry Groups: A Nationwide Cohort Study with More Than 70 Million Person-Years of Follow-Up
      Seong-Uk Baek, Woo-Ri Lee, Ki-Bong Yoo, Jun-Hyeok Choi, Kyung-Eun Lee, Wanhyung Lee, Jin-Ha Yoon
      Cancers.2022; 14(21): 5219.     CrossRef
    • Update on Diagnosis and Treatment of Colorectal Cancer
      Chan Wook Kim
      The Ewha Medical Journal.2022;[Epub]     CrossRef
    • Analysis of prognostic factors through survival rate analysis of oral squamous cell carcinoma patients treated at the National Cancer Center: 20 years of experience
      Yong-Seok Choi, Min Gyeong Kim, Jong-Ho Lee, Joo-Yong Park, Sung-Weon Choi
      Journal of the Korean Association of Oral and Maxillofacial Surgeons.2022; 48(5): 284.     CrossRef
    • Colorectal cancer mortality trends in the era of cancer survivorship in Korea: 2000–2020
      Min Hyun Kim, Sanghee Park, Nari Yi, Bobae Kang, In Ja Park
      Annals of Coloproctology.2022; 38(5): 343.     CrossRef
    • Clinical Efficacy of Hypofractionated Proton Beam Therapy for Intrahepatic Cholangiocarcinoma
      Tae Hyun Kim, Sang Myung Woo, Woo Jin Lee, Jung Won Chun, Yu Ri Cho, Bo Hyun Kim, Young-Hwan Koh, Sang Soo Kim, Eun Sang Oh, Do Yeul Lee, Sung Uk Lee, Yang-Gun Suh, Sung Ho Moon, Joong-Won Park
      Cancers.2022; 14(22): 5561.     CrossRef
    • Progression of Low-Risk Papillary Thyroid Microcarcinoma During Active Surveillance: Interim Analysis of a Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma in Korea
      Eun Kyung Lee, Jae Hoon Moon, Yul Hwangbo, Chang Hwan Ryu, Sun Wook Cho, June Young Choi, Eun-Jae Chung, Woo-Jin Jeong, Yuh-Seog Jung, Junsun Ryu, Su-jin Kim, Min Joo Kim, Yeo Koon Kim, Chang Yoon Lee, Ji Ye Lee, Hyeong Won Yu, Jeong Hun Hah, Kyu Eun Lee,
      Thyroid.2022; 32(11): 1328.     CrossRef
    • The risk of osteoporotic fractures after gastrectomy: Findings from the Korean national sample cohort database (2002-2019)
      Il Yun, Kyungduk Hurh, Sung Hoon Jeong, Eun-Cheol Park, Sung-In Jang
      Frontiers in Oncology.2022;[Epub]     CrossRef
    • Impact of modifiable reproductive factors on cancer incidence and mortality in Korea: a systematic review protocol
      Seo-Hee Kim, Mi Ah Han
      BMJ Open.2022; 12(11): e067826.     CrossRef
    • Traditional Korean Medicine Treatment for Sequelae After Surgery in Prostate Cancer Patients: Two Case Report
      Kwon-jun Jang, Jung-min Yang, Woo-seok Hwang, Beom-joon Lee
      The Journal of Internal Korean Medicine.2022; 43(5): 795.     CrossRef
    • NGS-based targeted gene mutational profiles in Korean patients with pancreatic cancer
      Kwangrok Jung, Sejoon Lee, Hee Young Na, Ji-Won Kim, Jong-Chan Lee, Jin-Hyeok Hwang, Jin Won Kim, Jaihwan Kim
      Scientific Reports.2022;[Epub]     CrossRef
    • A Survey on the Quality of Life of Prostate Cancer Patients in Korean Prostate Cancer Patients Association
      Yun-Sok Ha, Kwang Taek Kim, Wook Nam, Hongzoo Park, Sangjun Yoo, Chan Ho Lee, Ho Seok Chung, Woo Suk Choi, Jiyoun Kim, Jaeeun Shin, Jeong Hyun Kim, Cheol Kwak
      The Korean Journal of Urological Oncology.2022; 20(4): 265.     CrossRef
    • Comparison of Gastric Cancer Screening Strategies between Helicobacter pylori-infected, -eradicated, and -naive Individuals
      Sun-Young Lee
      The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2022; 22(4): 313.     CrossRef
    • Omission of chemotherapy for hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer: patterns of treatment and outcomes from the Korean Breast Cancer Society Registry
      Hannah Lois Kangleon-Tan, Jongmin Sim, Ji Young You, Eun-Shin Lee, Haemin Lee, Sun Moon Yang, Min-Ki Seong, Eun Hwa Park, Seok Jin Nam, Min Ho Park, Seokwon Lee, Woo-Chan Park, Rogelio G. Kangleon, Crisostomo B. Dy, Soo Youn Bae, Seung Pil Jung
      Annals of Surgical Treatment and Research.2022; 103(6): 313.     CrossRef
    • Does fragmented cancer care affect survival? Analysis of gastric cancer patients using national insurance claim data
      Dong-Woo Choi, Sun Jung Kim, Dong Jun Kim, Yoon-Jung Chang, Dong Wook Kim, Kyu-Tae Han
      BMC Health Services Research.2022;[Epub]     CrossRef
    • Clinical utilization of radiation therapy in Korea between 2017 and 2019
      Eunji Kim, Won Il Jang, Kwangmo Yang, Mi-Sook Kim, Hyung Jun Yoo, Eun Kyung Paik, Heejin Kim, Jaesun Yoon
      Radiation Oncology Journal.2022; 40(4): 251.     CrossRef
    • Effects of Education Program for Combined Management of Lymphedema with regard to Breast Cancer Patients with Axillary Lymph Node Dissection: A Quasi-Experimental Study
      Soohyun Kim, Eunjung Ryu
      Asian Oncology Nursing.2022; 22(4): 214.     CrossRef
    • The National Hospice and Palliative Care registry in Korea
      Kyuwoong Kim, Bohyun Park, Bonju Gu, Eun Jeong Nam, Sue Hyun Kye, Jin Young Choi
      Epidemiology and Health.2022; 44: e2022079.     CrossRef
    • Awareness of and practice toward cancer prevention recommendations: results of the Korean National Cancer Prevention Awareness and Practice Survey in 2021
      Jin-Kyoung Oh, Eunjung Park, Byungmi Kim, Yoon-Jung Choi, E Hwa Yun, Min Kyung Lim, Jeong-Soo Im, Eun Young Park
      Epidemiology and Health.2022; 44: e2022068.     CrossRef
    • Association of the inflammatory balance of diet and lifestyle with colorectal cancer among Korean adults: a case-control study
      Shinyoung Jun, Jeonghee Lee, Jae Hwan Oh, Hee Jin Chang, Dae Kyung Sohn, Aesun Shin, Jeongseon Kim
      Epidemiology and Health.2022; 44: e2022084.     CrossRef

    • PubReader PubReader
    • ePub LinkePub Link
    • Cite
      CITE
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2019
      Cancer Res Treat. 2022;54(2):330-344.   Published online March 16, 2022
      DOI: https://doi.org/10.4143/crt.2022.128
      Close
    • XML DownloadXML Download
    • 0
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2019
    Image Image Image Image Image Image Image
    Fig. 1 The five common sites of cancer incidence by age group and sex for 2019 in Korea. (A) Men. (B) Women. Numbers in parentheses are age-specific incidence rates per 100,000. CNS, central nervous system.
    Fig. 2 Age-specific incidence rates of common cancers for 2019 in Korea. (A) Men. (B) Women.
    Fig. 3 Annual age-standardized cancer incidence and mortality rates by sex for all sites from 1983 to 2019 in Korea. Age standardization was based on Segi’s world standard population.
    Fig. 4 Trends in age-standardized incidences of selected cancers by sex from 1999 to 2019 in Korea. (A) Men. (B) Women. Age standardization was based on Segi’s world standard population.
    Fig. 5 Trends in age-standardized mortalities of selected cancers by sex from 1983 to 2019 in Korea. (A) Men. (B) Women. Age standardization was based on Segi’s world standard population. a)Cancers of cervix uteri, corpus uteri, and unspecified combined (C53–C55), due to their unclear classifications in the past.
    Fig. 6 Five-year relative survival rates by stage at diagnosis and stage distribution of selected cancers by sex in Korea, 2015–2019. (A) Men. (B) Women. Staging according to the Surveillance, Epidemiology, and End Results stage categories. For each cancer type, stage categories do not total 100% because sufficient information was not available to stage all cases. a)Includes the gallbladder and other/unspecified parts of the biliary tract.
    Fig. 7 Prevalent cases of common cancers by time since cancer diagnosis. Prevalent cases were defined as the number of cancer patients alive on January 1, 2020 among all cancer patients diagnosed between 1999 and 2019.

    Fig. 1

    Fig. 2

    Fig. 3

    Fig. 4

    Fig. 5

    Fig. 6

    Fig. 7

    Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2019

    Cancer incidence, deaths and prevalence by sex in Korea, 2019

    Site/Type New cases Deaths Prevalent casesa)
    Both sexes Men Women Both sexes Men Women Both sexes Men Women
    All sites 254,718 134,180 120,538 81,203 50,281 30,922 2,147,503 943,518 1,203,985
    Lip, oral cavity, and pharynx 3,969 2,863 1,106 1,298 997 301 29,516 19,723 9,793
    Esophagus 2,870 2,573 297 1,554 1,425 129 12,086 10,769 1,317
    Stomach 29,493 19,761 9,732 7,624 4,956 2,668 318,948 210,689 108,259
    Colon and rectum 29,030 17,119 11,911 8,880 5,016 3,864 279,717 165,962 113,755
    Liver 15,605 11,541 4,064 10,586 7,784 2,802 75,261 56,420 18,841
    Gallbladderb) 7,383 3,896 3,487 4,988 2,568 2,420 25,505 13,185 12,320
    Pancreas 8,099 4,150 3,949 6,396 3,424 2,972 14,964 7,562 7,402
    Larynx 1,222 1,154 68 318 289 29 11,902 11,205 697
    Lung 29,960 20,331 9,629 18,574 13,698 4,876 103,108 62,105 41,003
    Breast 24,933 113 24,820 2,643 21 2,622 259,116 944 258,172
    Cervix uteri 3,273 - 3,273 898 - 898 58,983 - 58,983
    Corpus uteri 3,287 - 3,287 358 - 358 30,946 - 30,946
    Ovary 2,888 - 2,888 1,234 - 1,234 24,259 - 24,259
    Prostate 16,803 16,803 - 2,047 2,047 - 108,870 108,870 -
    Testis 325 325 - 19 19 - 4,046 4,046 -
    Kidney 6,026 4,155 1,871 983 666 317 50,674 34,270 16,404
    Bladder 4,895 3,984 911 1,550 1,167 383 39,963 32,592 7,371
    Brain and CNS 1,981 1,070 911 1,416 756 660 12,934 6,650 6,284
    Thyroid 30,676 7,516 23,160 373 109 264 462,151 84,565 377,586
    Hodgkin lymphoma 308 181 127 57 33 24 3,436 2,115 1,321
    Non-Hodgkin lymphoma 5,388 3,117 2,271 1,856 1,081 775 37,971 21,544 16,427
    Multiple myeloma 1,831 997 834 961 527 434 7,741 4,064 3,677
    Leukemia 3,738 2,108 1,630 1,911 1,143 768 25,538 14,178 11,360
    Other and ill-defined 20,735 10,423 10,312 4,679 2,555 2,124 149,868 72,060 77,808

    CNS, central nervous system.

    a)Limited-duration prevalent cases on January 1, 2019. These are patients who were diagnosed between January 1, 1999 and December 31, 2019 and who were alive on January 1, 2020. Multiple primary cancer cases were counted multiple times,

    b)Includes the gallbladder and other/unspecified parts of the biliary tract.

    Crude and age-standardized cancer incidence rates by sex in Korea, 2019

    Site/Type Crude incidence rate per 100,000 Age-standardized incidence rate per 100,000a)
    Both sexes Men Women Both sexes Men Women
    All sites 496.2 523.9 468.5 275.4 296.6 267.4
    Lip, oral cavity, and pharynx 7.7 11.2 4.3 4.3 6.5 2.4
    Esophagus 5.6 10.0 1.2 2.8 5.3 0.6
    Stomach 57.4 77.2 37.8 29.6 42.4 18.4
    Colon and rectum 56.5 66.8 46.3 28.7 37.0 21.4
    Liver 30.4 45.1 15.8 15.6 25.0 7.1
    Gallbladderb) 14.4 15.2 13.6 6.5 8.0 5.3
    Pancreas 15.8 16.2 15.3 7.6 8.8 6.6
    Larynx 2.4 4.5 0.3 1.2 2.4 0.1
    Lung 58.4 79.4 37.4 27.7 41.7 16.9
    Breast 48.6 0.4 96.5 30.4 0.3 60.5
    Cervix uteri 6.4 - 12.7 4.0 - 8.0
    Corpus uteri 6.4 - 12.8 4.0 - 7.9
    Ovary 5.6 - 11.2 3.5 - 7.0
    Prostate 32.7 65.6 - 15.5 34.3 -
    Testis 0.6 1.3 - 0.6 1.2 -
    Kidney 11.7 16.2 7.3 6.8 9.8 4.1
    Bladder 9.5 15.6 3.5 4.4 8.2 1.4
    Brain and CNS 3.9 4.2 3.5 2.9 3.2 2.6
    Thyroid 59.8 29.3 90.0 42.9 21.0 65.6
    Hodgkin lymphoma 0.6 0.7 0.5 0.5 0.6 0.4
    Non-Hodgkin lymphoma 10.5 12.2 8.8 6.3 7.8 5.0
    Multiple myeloma 3.6 3.9 3.2 1.8 2.1 1.5
    Leukemia 7.3 8.2 6.3 5.6 6.7 4.7
    Other and ill-defined 40.4 40.7 40.1 21.9 24.3 20.0

    CNS, central nervous system.

    a)Age-adjusted using the Segi’s world standard population,

    b)Includes the gallbladder and other/unspecified parts of the biliary tract.

    The top 10 leading causes of death in Korea, 2019

    Rank Cause of death No. of deaths Percentage of all deaths Age-standardized death rate per 100,000a)
    All causes 295,039 100.0 254.4
    1 Cancer 81,203 27.5 72.2
    2 Heart disease 31,030 10.5 24.6
    3 Cerebrovascular disease 21,586 7.3 16.9
    4 Pneumonia 23,168 7.9 16.4
    5 Intentional self-harm (suicide) 13,799 4.7 18.4
    6 Diabetes mellitus 8,102 2.7 6.4
    7 Disease of liver 6,496 2.2 6.8
    8 Chronic lower respiratory diseases 6,176 2.1 4.4
    9 Hypertensive diseases 5,631 1.9 3.9
    10 Transport accidents 4,221 1.4 5.0
    Others 93,698 31.8 79.5

    Source: Mortality Data, 2019, Statistics Korea [1].

    a)Age-adjusted using the Segi’s world standard population.

    Crude and age-standardized cancer mortality rates by sex in Korea, 2019

    Site/Type Crude mortality rate per 100,000 Age-standardized mortality rate per 100,000a)
    Both sexes Men Women Both sexes Men Women
    All sites 158.2 196.3 120.2 72.2 103.6 48.7
    Lip, oral cavity, and pharynx 2.5 3.9 1.2 1.2 2.1 0.5
    Esophagus 3.0 5.6 0.5 1.4 2.9 0.2
    Stomach 14.9 19.4 10.4 6.7 10.3 4.0
    Colon and rectum 17.3 19.6 15.0 7.6 10.3 5.4
    Liver 20.6 30.4 10.9 9.9 16.4 4.2
    Gallbladderb) 9.7 10.0 9.4 4.1 5.1 3.2
    Pancreas 12.5 13.4 11.6 5.6 7.1 4.4
    Larynx 0.6 1.1 0.1 0.3 0.6 0.0
    Lung 36.2 53.5 19.0 15.6 27.1 7.0
    Breast 5.1 0.1 10.2 2.9 0.0 5.5
    Cervix uteri 1.7 - 3.5 0.9 - 1.7
    Corpus uteri 0.7 - 1.4 0.4 - 0.7
    Ovary 2.4 - 4.8 1.2 - 2.4
    Prostate 4.0 8.0 - 1.5 4.0 -
    Testis 0.0 0.1 - 0.0 0.1 -
    Kidney 1.9 2.6 1.2 0.9 1.4 0.4
    Bladder 3.0 4.6 1.5 1.2 2.3 0.4
    Brain and CNS 2.8 3.0 2.6 1.7 2.0 1.4
    Thyroid 0.7 0.4 1.0 0.3 0.2 0.3
    Hodgkin lymphoma 0.1 0.1 0.1 0.1 0.1 0.0
    Non-Hodgkin lymphoma 3.6 4.2 3.0 1.7 2.3 1.2
    Multiple myeloma 1.9 2.1 1.7 0.8 1.0 0.6
    Leukemia 3.7 4.5 3.0 2.1 2.8 1.5
    Other and ill-defined 9.1 10.0 8.3 4.3 5.6 3.3

    CNS, central nervous system.

    a)Age-adjusted using the world standard population,

    b)Includes the gallbladder and other/unspecified parts of the biliary tract.

    Trends in cancer incidence and mortality rates from 1999 to 2019 in Korea, both sexes

    Site/Type Incidence Mortality
    1999 2019 Trend 1 Trend 2 Trend 3 1999 2019 Trend 1 Trend 2 Trend 3
    Years APC Years APC Years APC Years APC Years APC Years APC
    All sites 212.1 275.4 1999–2012 3.3a) 2012–2015 −5.3a) 2015–2019 1.1 115.1 72.2 1999–2002 0.9 2002–2013 −2.7a) 2013–2019 −3.3a)
    Lip, oral cavity, and pharynx 3.6 4.3 1999–2019 0.7a) - - - - 1.1 1.2 1999–2019 −1.8a) - - - -
    Esophagus 4.1 2.8 1999–2017 −2.2a) 2017–2019 1.8 - - 3.1 1.4 1999–2019 −4.43a) - - - -
    Stomach 43.6 30.4 1999–2011 −0.2 2011–2018 −4.6a) - - 23.8 7.1 1999–2002 −2.6a) 2002–2010 −6.2a) 2010–2018 −7.4a)
    Colon and rectum 20.5 28.7 1999–2006 7.3a) 2006–2011 2.9a) 2011–2019 4.0a) 7.8 7.6 1999–2003 6.4a) 2003–2012 −0.5 2012–2019 −3.6a)
    Liver 27.9 15.6 1999–2009 −1.6a) 2009–2019 −4.1a) - - 20.6 9.9 1999–2002 0.6 2002–2014 −3.7a) 2014–2019 −6.1a)
    Gallbladderb) 6.5 6.5 1999–2004 1.5 2004–2019 −0.4a) - - 5.2 4.1 1999–2001 7.6 2001–2014 −2.8a) 2014–2019 0.0
    Pancreas 5.6 7.6 1999–2019 1.5a) - - - - 5.5 5.6 1999–2019 0.1 - - - -
    Larynx 2.4 1.2 1999–2019 −3.5a) - - - - 1.6 0.3 1999–2005 −8.1a) 2005–2008 −15.5a) 2008–2019 −7.2a)
    Lung 28.5 27.7 1999–2011 0.1 2011–2015 −1.4a) 2015–2019 0.6 22.5 15.6 1999–2001 3.8 2001–2014 −2.0a) 2014–2019 −3.9a)
    Breast 11.0 30.4 1999–2007 6.4a) 2007–2019 4.4a) - - 2.3 2.9 1999–2004 2.9a) 2004–2019 0.8a) - -
    Cervix uteri 8.6 4.0 1999–2007 −4.7a) 2007–2019 −3.0a) - - 1.4 0.9 1999–2003 10.1a) 2003–2008 −7.2a) 2008–2019 −4.0a)
    Corpus uteri 1.4 4.0 1999–2019 5.1a) - - - - 0.1 0.4 1999–2003 36.0a) 2003–2019 2.4a) - -
    Ovary 2.7 3.5 1999–2019 1.7a) - - - - 0.9 1.2 1999–2019 0.6a) - - - -
    Prostate 3.1 15.5 1999–2009 14.9a) 2009–2015 0.5 2015–2019 7.3a) 0.9 1.5 1999–2002 15.3a) 2002–2011 1.6a) 2011–2019 −1.4a)
    Testis 0.3 0.6 1999–2019 4.7a) - - - - 0.0 0.0 1999–2019 −2.1a) - - - -
    Kidney 3.0 6.8 1999–2009 6.3a) 2009–2019 2.3a) - - 1.1 0.9 1999–2016 −0.1 2016–2019 −6.6a) - -
    Bladder 4.7 4.4 1999–2004 1.8a) 2004–2019 −1.0a) - - 1.3 1.2 1999–2002 9.3a) 2002–2005 −6.1 2005–2019 −1.5a)
    Brain and CNS 2.9 2.9 1999–2019 0.2 - - - 1.9 1.7 1999–2003 4.1a) 2003–2008 −4.4a) 2008–2019 −0.7a)
    Thyroid 6.5 42.9 1999–2011 22.5a) 2011–2016 −12.3a) 2016–2019 6.2 0.4 0.3 1999–2003 7.5a) 2003–2019 −4.6a) - -
    Hodgkin lymphoma 0.3 0.5 1999–2011 4.9a) 2011–2019 1.3 - - 0.0 0.1 1999–2004 23.7a) 2004–2019 −2.1a) - -
    Non-Hodgkin lymphoma 4.3 6.3 1999–2019 2.3a) - - - - 2.1 1.7 1999–2019 −1.1a) - - - -
    Multiple myeloma 1.0 1.8 1999–2012 3.7a) 2012–2019 1.2a) - - 0.6 0.8 1999–2003 12.7a) 2003–2016 0.9 2016–2019 −7.0a)
    Leukemia 4.7 5.6 1999–2019 0.9a) - - - - 2.9 2.1 1999–2019 −1.8a) - - - -
    Other and ill-defined 15.0 21.9 1999–2001 −0.9 2001–2007 3.7a) 2007–2019 1.8a) 7.8 4.3 1999–2019 −2.8a) - - - -

    APC was calculated using age-standardized incidence data based on the Segi’s world standard population. APC, annual percentage change; CNS, central nervous system.

    a)Significantly different from zero (p < 0.05),

    b)Includes the gallbladder and other/unspecified parts of the biliary tract.

    Trends in the 5-year relative survival rates (%) by sex and year of diagnosis from 1993 to 2019 in Korea

    Site/Type Both sexes Men Women
    1993–1995 1996–2000 2001–2005 2006–2010 2011–2015 2015–2019 Changea) 1993–1995 1996–2000 2001–2005 2006–2010 2011–2015 2015–2019 Changea) 1993–1995 1996–2000 2001–2005 2006–2010 2011–2015 2015–2019 Changea)
    All sites 42.9 45.2 54.1 65.5 70.7 70.7 27.8 33.2 36.3 45.6 56.9 63.1 64.5 31.3 55.2 56.4 64.3 74.4 78.3 77.3 22.1
    All sites excluding thyroid 41.2 43.4 50.8 59.0 64.2 66.5 25.3 32.7 35.8 44.7 54.6 60.3 62.4 29.7 52.6 53.5 59.1 65.0 69.4 71.5 19.0
    Lip, oral cavity, and pharynx 42.2 47.4 54.5 61.1 65.4 68.8 26.6 36.6 41.7 49.6 56.9 61.8 65.9 29.3 59.4 64.5 68.1 72.1 74.5 76.2 16.8
    Esophagus 14.0 15.7 21.6 30.0 36.5 40.9 26.9 13.0 14.8 20.8 29.3 36.2 40.6 27.6 25.0 25.9 29.8 37.3 39.6 43.4 18.4
    Stomach 43.9 47.3 58.0 68.4 75.9 77.5 33.6 44.0 47.6 58.7 69.1 76.8 78.3 34.3 43.7 46.8 56.6 67.0 74.0 75.8 32.1
    Colon and rectum 56.2 58.9 66.9 73.9 76.1 74.3 18.1 56.6 59.8 68.8 75.8 77.8 75.5 18.9 55.7 57.7 64.4 71.1 73.6 72.6 16.9
    Liver 11.8 14.1 20.5 28.3 34.4 37.7 25.9 10.8 13.8 20.4 28.3 34.9 38.3 27.5 15.1 15.1 20.9 28.3 32.8 35.8 20.7
    Gallbladderb) 18.7 20.7 23.1 26.9 28.7 28.5 9.8 18.0 21.1 23.5 27.8 29.5 28.8 10.8 19.3 20.3 22.7 26.0 28.0 28.1 8.8
    Pancreas 10.6 8.7 8.4 8.6 10.8 13.9 3.3 10.0 8.3 8.4 8.3 10.3 13.0 3.0 11.5 9.3 8.4 8.8 11.5 14.9 3.4
    Larynx 61.6 63.3 66.5 73.2 75.3 80.4 18.8 62.2 63.7 67.1 73.5 75.7 80.5 18.3 56.3 58.9 58.7 68.0 69.1 78.9 22.6
    Lung 12.5 13.6 16.6 20.3 27.6 34.7 22.2 11.6 12.4 15.3 18.0 23.3 28.9 17.3 15.8 17.5 20.2 26.0 37.4 47.4 31.6
    Breast 79.2 83.6 88.7 91.2 92.8 93.6 14.4 77.1 84.3 87.5 89.9 90.8 93.3 16.2 79.3 83.6 88.7 91.2 92.8 93.6 14.3
    Cervix uteri 78.3 80.3 81.5 80.7 80.3 80.5 2.2 - - - - - - - 78.3 80.3 81.5 80.7 80.3 80.5 2.2
    Corpus uteri 82.9 82.0 84.7 86.5 87.7 89.0 6.1 - - - - - - - 82.9 82.0 84.7 86.5 87.7 89.0 6.1
    Ovary 60.1 59.4 61.7 61.3 64.8 64.5 4.4 - - - - - - - 60.1 59.4 61.7 61.3 64.8 64.5 4.4
    Prostate 59.1 69.4 81.0 92.0 94.2 94.4 35.3 59.1 69.4 81.0 92.0 94.2 94.4 35.3 - - - - - - -
    Testis 87.4 90.4 90.7 93.2 94.9 95.0 7.6 87.4 90.4 90.7 93.2 94.9 95.0 7.6 - - - - - - -
    Kidney 64.2 67.0 73.7 78.6 82.5 84.7 20.5 63.4 65.4 73.1 78.5 82.1 84.7 21.3 65.8 70.3 74.9 79.0 83.4 84.8 19.0
    Bladder 70.7 73.6 76.0 77.3 76.4 76.5 5.8 71.6 75.1 77.8 79.3 78.4 78.1 6.5 67.2 67.2 69.1 69.2 68.5 70.0 2.8
    Brain and CNS 40.4 39.9 41.0 42.9 41.7 41.4 1.0 39.1 38.7 40.3 41.4 40.4 40.0 0.9 42.3 41.4 41.8 44.6 43.3 43.0 0.7
    Thyroid 94.5 95.0 98.4 100.0 100.2 100.0 5.5 87.9 89.7 96.0 100.2 100.6 100.3 12.4 95.7 96.0 98.7 99.9 100.1 99.9 4.2
    Hodgkin lymphoma 70.2 71.9 76.7 81.1 82.3 85.3 15.1 69.4 69.3 74.7 80.8 81.8 84.5 15.1 71.5 77.3 80.7 81.6 83.3 86.5 15.0
    Non-Hodgkin lymphoma 48.3 51.1 56.0 59.4 62.8 64.5 16.2 46.8 49.6 55.0 59.2 62.9 65.3 18.5 50.6 53.3 57.5 59.7 62.8 63.5 12.9
    Multiple myeloma 23.7 21.0 29.7 34.9 41.5 49.1 25.4 23.2 19.1 29.9 35.1 41.1 49.7 26.5 24.1 23.3 29.5 34.7 42.1 48.6 24.5
    Leukemia 27.5 34.3 42.0 47.7 52.0 54.5 27.0 27.3 33.3 41.8 46.9 52.2 54.2 26.9 27.8 35.5 42.2 48.7 51.7 55.0 27.2
    Other and ill-defined 44.5 48.3 57.9 67.7 72.7 75.4 30.9 39.6 44.7 54.1 63.8 69.3 72.5 32.9 50.1 52.6 62.0 71.6 76.2 78.3 28.2

    CNS, central nervous system.

    a)Absolute percentage change in 5-year relative survival from 1993 to 1995 and 2015 to 2019,

    b)Includes the gallbladder and other/unspecified parts of the biliary tract.

    Crude and age-standardized rates of cancer prevalence by sex on January 1, 2020 in Korea

    Site/Type Crude prevalence rate per 100,000a) Age-standardized prevalence rate per 100,000b)
    Both sexes Men Women Both sexes Men Women
    All sites 4,183.1 3,684.3 4,679.7 2,305.1 2,081.4 2,612.8
    Lip, oral cavity, and pharynx 57.5 77.0 38.1 32.2 44.6 21.2
    Esophagus 23.5 42.1 5.1 11.4 22.2 2.4
    Stomach 621.3 822.7 420.8 306.6 441.6 194.2
    Colon and rectum 544.9 648.1 442.1 266.0 349.9 197.2
    Liver 146.6 220.3 73.2 77.5 123.3 35.8
    Gallbladderc) 49.7 51.5 47.9 23.0 27.1 19.7
    Pancreas 29.1 29.5 28.8 15.3 16.5 14.4
    Larynx 23.2 43.8 2.7 11.0 23.0 1.2
    Lung 200.8 242.5 159.4 98.0 128.6 74.4
    Breast 504.7 3.7 1,003.5 291.5 2.0 574.2
    Cervix uteri 114.9 0.0 229.3 65.1 - 127.6
    Corpus uteri 60.3 0.0 120.3 34.8 - 68.6
    Ovary 47.3 0.0 94.3 29.7 - 59.2
    Prostate 212.1 425.1 0.0 91.8 213.8 -
    Testis 7.9 15.8 0.0 7.0 13.7 -
    Kidney 98.7 133.8 63.8 55.3 78.5 34.2
    Bladder 77.8 127.3 28.6 35.7 66.8 11.5
    Brain and CNS 25.2 26.0 24.4 20.7 21.9 19.4
    Thyroid 900.2 330.2 1,467.6 563.7 212.3 913.4
    Hodgkin lymphoma 6.7 8.3 5.1 5.4 6.4 4.3
    Non-Hodgkin lymphoma 74.0 84.1 63.8 48.1 57.6 39.1
    Multiple myeloma 15.1 15.9 14.3 7.6 8.7 6.7
    Leukemia 49.7 55.4 44.2 44.0 49.3 38.6
    Other and ill-defined 291.9 281.4 302.4 163.7 173.7 155.4

    CNS, central nervous system.

    a)Crude prevalence rate: number of prevalent cases divided by the corresponding person-years of observation. Prevalent cases were defined as patients who were diagnosed between January 1, 1999 and December 31, 2019 and who were alive on January 1, 2020. Multiple primary cancer cases were counted multiple times,

    b)Age-adjusted using the Segi's world standard opulation

    c)Includes the gallbladder and other/unspecified parts of the biliary tract
    Table 1 Cancer incidence, deaths and prevalence by sex in Korea, 2019

    CNS, central nervous system.

    Limited-duration prevalent cases on January 1, 2019. These are patients who were diagnosed between January 1, 1999 and December 31, 2019 and who were alive on January 1, 2020. Multiple primary cancer cases were counted multiple times,

    Includes the gallbladder and other/unspecified parts of the biliary tract.

    Table 2 Crude and age-standardized cancer incidence rates by sex in Korea, 2019

    CNS, central nervous system.

    Age-adjusted using the Segi’s world standard population,

    Includes the gallbladder and other/unspecified parts of the biliary tract.

    Table 3 The top 10 leading causes of death in Korea, 2019

    Source: Mortality Data, 2019, Statistics Korea [1].

    Age-adjusted using the Segi’s world standard population.

    Table 4 Crude and age-standardized cancer mortality rates by sex in Korea, 2019

    CNS, central nervous system.

    Age-adjusted using the world standard population,

    Includes the gallbladder and other/unspecified parts of the biliary tract.

    Table 5 Trends in cancer incidence and mortality rates from 1999 to 2019 in Korea, both sexes

    APC was calculated using age-standardized incidence data based on the Segi’s world standard population. APC, annual percentage change; CNS, central nervous system.

    Significantly different from zero (p < 0.05),

    Includes the gallbladder and other/unspecified parts of the biliary tract.

    Table 6 Trends in the 5-year relative survival rates (%) by sex and year of diagnosis from 1993 to 2019 in Korea

    CNS, central nervous system.

    Absolute percentage change in 5-year relative survival from 1993 to 1995 and 2015 to 2019,

    Includes the gallbladder and other/unspecified parts of the biliary tract.

    Table 7 Crude and age-standardized rates of cancer prevalence by sex on January 1, 2020 in Korea

    CNS, central nervous system.

    Crude prevalence rate: number of prevalent cases divided by the corresponding person-years of observation. Prevalent cases were defined as patients who were diagnosed between January 1, 1999 and December 31, 2019 and who were alive on January 1, 2020. Multiple primary cancer cases were counted multiple times,

    Age-adjusted using the Segi's world standard opulation

    Includes the gallbladder and other/unspecified parts of the biliary tract

    Table 1

    Table 2

    Table 3

    Table 4

    Table 5

    Table 6

    Table 7

    Cancer Res Treat : Cancer Research and Treatment
    © Korean Cancer Association.
    Close layer
    TOP